# **Supplemental Online Content**

eMethods 1. MOOSE checklist	2
eMethods 2. Documentation of deviations from the pre-registered protocol	4
eMethods 3. Search strategy supplemental information	7
eMethods 4. PECOS inclusion/exclusion criteria	11
eMethods 5. Modified Newcastle Ottawa Scale (NOS)	12
eMethods 6. Directed Acyclic Graph (DAG)	13
eMethods 7. Confounder matrix judgement criteria	14
eMethods 8. Statistical approach	15
eMethods 9. References	16
eTable 1. Studies excluded at full-text screening	17
eTable 2. Tobacco and mood disorder study characteristics	27
eTable 3. Tobacco and anxiety disorder study characteristics	41
eTable 4. Tobacco and psychotic disorder study characteristics	43
eTable 5. Cannabis and mood disorder study characteristics	45
eTable 6. Cannabis and anxiety disorder study characteristics	47
eTable 7. Cannabis and psychotic disorder study characteristics	
eTable 8. NOS quality assessment	50
eTable 9. Summary of NOS ratings and mean scores by exposure/outcome	52
eTable 10. Luis-Kanamori (LFK) index and asymmetry rating for primary meta-analyses	53
eTable 11. Subgroup analyses for tobacco and mood disorders	54
eTable 12. Meta-regression analyses for tobacco and mood disorders	54
eFigure 1. PRISMA flow-chart	55
eFigure 2. Unadjusted meta-analysis of tobacco use and mood disorders	57
eFigure 4. Unadjusted meta-analysis of tobacco use and psychotic disorders	59
eFigure 5. Unadjusted meta-analysis of cannabis use and mood disorders	60
eFigure 6. Unadjusted meta-analysis of cannabis use and anxiety disorders	61
eFigure 7. Unadjusted meta-analysis of cannabis use and psychotic disorders	
eFigure 8. Summary matrix for tobacco use and mood disorders	63
eFigure 9. Summary matrix for tobacco use and anxiety disorders	
eFigure 10. Summary matrix for tobacco use and psychotic disorders	65
eFigure 11. Summary matrix for cannabis use and mood disorders	66
eFigure 12. Summary matrix for cannabis use and anxiety disorders	67
eFigure 13. Summary matrix for cannabis use and psychotic disorders	68
eFigure 14. Doi plot and LFK index for tobacco use and mood disorders	69
eFigure 15. Doi plot and LFK index for tobacco use and anxiety disorders	70
eFigure 16. Doi plot and LFK index for tobacco use and psychotic disorders	71
eFigure 17. Doi plot and LFK index for cannabis use and mood disorders	72
eFigure 18. Doi plot and LFK index for cannabis use and anxiety disorders	73
eFigure 19. Doi plot and LFK index for cannabis use and psychotic disorders	74

### eMethods 1. MOOSE checklist

## MOOSE Checklist for Meta-analyses of Observational Studies<sup>1</sup>

Item No	Recommendation	Reported	
Reporting	of background should include		
1	Problem definition	Introduction	
2	Hypothesis statement	Introduction	
3	Description of study outcome(s)	Eligibility Criteria	
4	Type of exposure or intervention used	Eligibility Criteria	
5	Type of study designs used	Eligibility Criteria	
6	Study population	Eligibility Criteria	
Reporting	of search strategy should include		
7	Qualifications of searchers (eg, librarians and investigators)	eMethods	
8	Search strategy, including time period included in the synthesis and key words	eMethods	
9	Effort to include all available studies, including contact with authors	eMethods	
10	Databases and registries searched	eMethods	
11	Search software used, name and version, including special features used (eg, explosion)	eMethods	
12	Use of hand searching (eg, reference lists of obtained articles)	eMethods	
13	List of citations located and those excluded, including justification	eTable1	
14	Method of addressing articles published in languages other than English	eMethods	
15	Method of handling abstracts and unpublished studies	eMethods	
16	Description of any contact with authors	eMethods	
Reporting	Reporting of methods should include		
17	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	Eligibility Criteria	
18	Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	Eligibility Criteria	
19	Documentation of how data were classified and coded (eg, multiple raters, blinding and interrater reliability)	Search and Selection; Data Extraction	
20	Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)	eMethods	
21	Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results	Data Extraction; eMethods	
22	Assessment of heterogeneity	Statistical Analysis	
23	Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	Statistical Analysis, eMethods	

24	Provision of appropriate tables and graphics	Results; Supplement	
Reporting of	of results should include		
25	Graphic summarizing individual study estimates and overall estimate	Figure 1-3	
26	Table giving descriptive information for each study included	eTable 2-7	
27	Results of sensitivity testing (eg, subgroup analysis)	eTable	
28	Indication of statistical uncertainty of findings	Results (CIs and PIs)	
Reporting of	Reporting of discussion should include		
29	Quantitative assessment of bias (eg, publication bias)	Meta-Biases; eFigure 10-15; Discussion	
30	Justification for exclusion (eg, exclusion of non-English language citations)	Eligibility Criteria; Discussion	
31	Assessment of quality of included studies	eTable 8 + 9	
Reporting of conclusions should include			
32	Consideration of alternative explanations for observed results	Discussion	
33	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	Discussion	
34	Guidelines for future research	Discussion	
35	Disclosure of funding source	Acknowledgements	

### eMethods 2. Documentation of deviations from the pre-registered protocol

Summary of protocol deviations informed by suggested structure<sup>2</sup> for reporting available online at: <a href="https://osf.io/q8stz/">https://osf.io/q8stz/</a>

## **Deviation (1):** Eligibility criteria – population characteristic

Description:	Change in inclusion criteria made during title/abstract screening to exclude
	studies where participants were selected based on health status (e.g. pregnant
	women, asthmatic) or other clinically meaningful characteristics (e.g. incarcerated
	persons).
Justification:	This amendment was made to reduce the substantial heterogeneity in
	populations, and was informed by recommendations from a previous review in
	this area which cites highly specific samples as a barrier to interpretation of
	evidence synthesis <sup>3</sup>
Impact:	<b>Major</b> ; reduced the total number of included studies and applicability of the review
	to other populations i.e. does the association of smoking with subsequent mental
	illness differ in different populations? Furthermore, evidence of positive
	association across heterogeneous populations would have added further
	evidence to assessment of causality. However, also enabled a more targeted
	assessment of confounding bias in 'general population' studies.

### **Deviation (2):** Search strategy – citation searching tool

Description:	A citation chasing tool not pre-specified in the protocol was used for forward and backward citation searching ( <a href="https://estech.shinyapps.io/citationchaser/">https://estech.shinyapps.io/citationchaser/</a> ).
Justification:	The tool was not publicly available at the time of writing the pre-registration.
Impact:	Minor; may have yielded a more comprehensive search of records than achieved
	through standard manual approach, although also possible that some records
	missed due to software reliance on Lens.org database to compile all reference
	and/or citing records. These supplementary references were screened by one
	reviewer due to resource availability, which may have increased possible biases
	in screening.

### **Deviation (3):** Data synthesis – meta-analysis method

Description:	Change in pre-planned random-effects meta-analysis method from using Mantel-
	Haenszel (MH) method, to generic inverse variance method (GIV).
Justification:	MH method was originally selected due to recommendation by Cochrane
	Handbook as optimal approach for binary outcome data with few events. <sup>4</sup>
	However, it was discovered after protocol registration that this method is only
	applicable to raw data, rather than pre-calculated estimates - which was the target
	of the primary meta-analysis of adjusted effect estimates.
Impact:	Minor; still random-effects (i.e. assumption true effect varies from study to study)
	and GIV is a commonly implemented approach for random-effects meta-analysis.
	Under this method, the weight given to each study is the inverse of the variance
	of the effect estimate, which may have made the pooled estimate more precise.
	However, importantly, the synthesis of pre-calculated effect estimates would not
	have been possible using the MH method.

## **Deviation (4):** Data synthesis – unadjusted/minimally-adjusted

Description:	Change from pooling unadjusted and adjusted estimates separately, to pooling
	'minimally-adjusted' (i.e. age/sex, none) and adjusted estimates separately.
Justification:	Numerous studies didn't provide unadjusted estimates but estimates adjusted for
	age and sex. Some studies provided only estimates adjusted for age and sex as
	their maximally adjusted estimate. Given the aims of the review, we chose to treat
	these as 'minimally adjusted' results and these were pooled alongside crude
	estimates.
Impact:	Minor; including the estimates adjusted for age and/or sex in the unadjusted
	meta-analyses may have slightly attenuated the difference between adjusted vs.
	unadjusted meta-analyses. However, there was still an observed difference and a
	more in-depth assessment of confounding bias was also conducted using a
	subgroup analyses informed by the confounder matrix judgements.

### **Deviation (5):** Data synthesis – confounder matrix

Description:	A confounding assessment tool, the 'confounder matrix'5 that was not pre-
	specified in the protocol was used to inform the assessment of control for
	confounding across the studies included in the primary meta-analyses.
Justification:	The tool was not publicly available at the time of writing the pre-registration.
Impact:	<b>Minor</b> ; in order to interpret the E-values, an assessment of important confounders
	controlled for was necessary and recommended by concept developers. 6 The use
	of a transparent, visual approach was selected as review team felt it aided
	interpretability.

### **Deviation (6):** Data synthesis – summary estimate (approximate RR vs. OR)

Description:	A change in summary estimate for the meta-analyses was made from the odds
	ratio (OR) to the risk ratio (RR).
Justification:	Given that E-values are assessed on the RR scale, and estimates required
	transformation if outcome prevalence >15%, we selected the square-root
	transformation available for OR à RR and HR à RR to increase consistency
	across the review. <sup>7,8</sup> Alternative methods required information frequently not
	provided by studies. <sup>8,9</sup> This approach has been employed in other published
	reviews. <sup>10</sup> For outcomes where prevalence was rare (e.g. psychotic disorder),
	estimates were pooled together without conversion. This is line with approaches
	employed in other reviews. <sup>11</sup>
Impact:	<b>Major</b> ; as a result, the pooled estimate reflects an 'approximate' RR. The review
	team felt this was the optimal approach for interpretability of the review. Risk
	ratios are also recommended as a preferred summary estimate by Cochrane
	Handbook, due to increased interpretability of the estimate. <sup>4</sup>

## **Deviation (7):** Data synthesis - subgroup analyses

Description:	An additional subgroup analysis using judgements from the confounder matrix was added, instead of the planned meta-regression using 'number of covariates'.
Justification:	Number of covariates was planned as a meta-regression to explore impact of control for confounding on the pooled estimate. However, this was felt to be less informative than information on 'important' confounders adjusted for from the confounder matrix assessment.
Impact:	<b>Minor</b> ; a quantitative exploration of bias due to inadequate confounding control was still performed.

## **Deviation (8):** Data synthesis – sensitivity analyses

Description:	A planned sensitivity analysis <i>excluding</i> studies not rated as 'high quality' was
	instead performed as a subgroup analysis. A planned sensitivity analysis
	excluding studies not using a validated outcome measure was not performed.
Justification:	A small number of studies were rated as high quality; therefore, it was deemed a
	better use of available information to compare estimates across 'low', 'moderate'
	and 'high' quality studies. There were few studies using non-validated outcome
	measures, and therefore a planned subgroup analysis by outcome type was
	deemed satisfactory explanation of the role of outcome measurement in pooled
	estimate.
Impact:	Minor; a quantitative exploration of the possible influence of study quality and
	outcome measure on pooled estimate was still performed.

### Deviation (9): Risk of bias in individual studies – additional modifications

Description:	Change from total score cut-off to distinguish quality of studies (i.e. low,
	moderate, high) to using a weighted approach to key items on the Newcastle
	Ottawa Scale. For details see <b>eMethods 5</b> .
Justification:	Total score approach has been criticised for not providing a nuanced assessment of possible sources of bias (e.g. a study could score >=7 with limited adjustment for confounding and substantial, or unclear, loss to follow-up). A weighted approach allows key sources of bias (i.e. confounding, attrition) to be preferentially considered in overall judgement of quality, and has been employed in other systematic reviews which assess risk factors for incident mental health conditions. <sup>12</sup>
Impact:	<b>Moderate</b> ; some studies that would have been rated as 'high' based on original cut-off (i.e. >=7) were instead rated as 'moderate' quality due to lack of information about attrition. However, we have also presented total scores in order to enable readers to have access to the overall 'score'.

## **Deviation (10):** E-values for individual studies versus overall synthesis

Description:	We planned to calculate E-values for individual studies, and for the overall meta- analyses using the extension of E-values to the random-effects meta-analysis but did not perform the latter.	
Justification:	Due to feasibility, it was decided that the E-values performed for individual studies in combination with the confounder matrix assessment was sufficient exploration of confounding bias.	
Impact:	<b>Minor</b> ; an assessment of confounding bias using E-values was still performed and impact considered on the overall synthesis. Other measures of uncertainty (e.g. 95Cls) were also considered in interpretation of results.	

### eMethods 3. Search strategy supplemental information

The search strategy for all databases have been provided below. The search terms and strategy were developed by the lead author (CB), reviewed and agreed amongst the review team and reviewed by a scientific librarian. Searches were initially performed in March 2021, and updated again in January 2022 and November 2022. Final searches were run on 18<sup>th</sup> November 2022.

#### Databases:

CINAHL (via EBSCOhost), Embase (via embase.com), MEDLINE (via PubMed), PsycINFO (via APA PsycNET). Searched from inception to present (i.e. point at which search performed). Base strategy was created in PubMed, which was adapted as required for the syntax and subject headings of the other databases used in the search. The following vocabulary databases were used to find equivalent terms: APA Thesaurus, CINAHL Headings and Emtree. For studies published in languages other than English, Google Translate was used to adequately translate the title, abstract and full text as required.

#### **Grey literature:**

Unpublished dissertations/theses were searched via the database ProQuest Dissertation & Theses.

#### Other sources:

- The shiny app 'citationchaser' (<a href="https://estech.shinyapps.io/citationchaser/">https://estech.shinyapps.io/citationchaser/</a>)<sup>13</sup> was used to perform forward and backward citation searching of: (1) included studies, and (2) identified relevant reviews.
- Authors of published conference abstracts without accompanying full-texts were contacted where
  possible to ascertain study eligibility and acquire relevant results.
- A defined list of 10 experts in the field were successfully contacted via e-mail for unpublished findings or 'file drawer' data that might fulfil inclusion criteria. The response rate was 100%. A list of contacted persons is available on request.

### Search field:

Text-words searched in Title/Abstract throughout all databases, except where otherwise specified.

#### Limits:

None applied (e.g. language, publication status) – not exclusion criteria for the review.

### De-duplication:

Applied in Endnote and Covidence.

### Full-text screening:

Studies were excluded following a hierarchy, as presented in **eTable 1**. As such, studies excluded on a higher-level criteria (e.g. not longitudinal, not binary) do not necessarily meet remaining criteria. Please note, exclusion on 'not longitudinal' refers to both cross-sectional studies, in addition to longitudinal studies with no eligible prospective association (i.e. temporal separation between exposure and outcome could not be established due to data collection methods or analysis).

### Missing data and non-retrievable full-texts:

All authors of studies excluded on 'FT not retrieved' or 'Missing data' were contacted where a corresponding e-mail address could be located. Reasons for non-retrieval include (1) author non-response, (2) no e-mail address located, and (3) authors no longer having access to the data.

## PubMed Search Strategy

All MeSH Terms exploded unless otherwise specified by 'MeSH Terms:noexp'

ID	Searches		
#1	"cannabis"[MeSH Terms] OR "marijuana abuse"[MeSH Terms] OR "marijuana		
	smoking"[MeSH Terms] OR cannabis[Title/Abstract] OR marijuana[Title/Abstract]		
	OR marihuana[Title/Abstract]		
#2	"tobacco use"[MeSH Terms] OR "tobacco products"[MeSH Terms] OR "tobacco		
	smoking"[MeSH Terms] OR "tobacco use disorder"[MeSH Terms] OR		
	cigar*[Title/Abstract] OR smok*[Title/Abstract] OR nicotin*[Title/Abstract] OR		
	tobacco[Title/Abstract]		
#3	#1 OR #2		
#4	"schizophrenia spectrum and other psychotic disorders"[MeSH Terms] OR		
	schizo*[Title/Abstract] OR psychosis[Title/Abstract] OR psychotic[Title/Abstract]		
#5	"mood disorders"[MeSH Terms] OR "bipolar and related disorders"[MeSH Terms]		
	OR "depression" [MeSH Terms] OR depress*[Title/Abstract] OR		
	bipolar[Title/Abstract] OR dysthymia[Title/Abstract] OR "mood		
	disorder*"[Title/Abstract]		
#6	"anxiety disorders"[MeSH Terms] OR "Anxiety"[MeSH Terms:noexp] OR		
	phobia*[Title/Abstract] OR panic[Title/Abstract] OR anxi*[Title/Abstract]		
#7	"Mental Disorders"[MeSH Terms:noexp] OR "mental illness*"[Title/Abstract] OR		
	"mental disorder*"[Title/Abstract] OR "psychiatric diagnos*"[Title/Abstract] OR		
	"psychiatric disorder*"[Title/Abstract]		
#8	#4 OR #5 OR #6 OR #7		
#9	"Epidemiologic Studies"[MeSH Terms:noexp] OR "cohort studies"[MeSH Terms]		
	OR "case control studies"[MeSH Terms] OR "case control stud*"[Title/Abstract] OR		
	"cohort stud*"[Title/Abstract] OR retrospective[Title/Abstract] OR		
	prospective[Title/Abstract] OR longitudinal[Title/Abstract] OR		
	inciden*[Title/Abstract] OR "follow up"[Title]		
#10	#3 AND #8 AND #9		

## <u>Embase</u>

Limits applied: MEDLINE limiter

ID	Searches			
#1	'cannabis'/exp/mj OR 'cannabis use'/exp/mj OR 'cannabis addiction'/exp/mj OR			
	cannabis:ab,ti OR marijuana:ab,ti OR marihuana:ab,ti			
#2	'tobacco'/exp/mj OR 'tobacco use'/exp/mj OR 'tobacco dependence'/exp/mj OR			
	cigar*:ab,ti OR smok*:ab,ti OR nicotin*:ab,ti OR tobacco:ab,ti			
#3	'psychosis'/exp/mj OR schizo*:ab,ti OR psychotic:ab,ti OR psychosis:ab,ti			
#4	'mood disorder'/exp/mj OR 'bipolar disorder'/exp/mj OR depress*:ab,ti OR 'mood			
	disorder*':ab,ti OR bipolar:ab,ti OR dysthymia:ab,ti			
#5	'anxiety disorder'/exp/mj OR phobia*:ab,ti OR panic:ab,ti OR anxi*:ab,ti			
#6	'mental disease'/mj OR 'mental illness*':ab,ti OR 'mental disorder*':ab,ti OR			
	'psychiatric disorder*':ab,ti OR 'psychiatric diagnos*':ab,ti			
#7	'epidemiology'/mj OR 'cohort analysis'/mj OR 'case control study'/exp/mj OR 'cohort			
	stud*':ab,ti OR 'case control stud*':ab,ti OR retrospective:ab,ti OR prospective:ab,ti			
	OR longitudinal:ab,ti OR inciden*:ab,ti OR 'follow up':ti			
#8	#1 OR #2			
#9	#3 OR #4 OR #5 OR #6			

#10	#7 AND #8 AND #9
#11	#7 AND #8 AND #9 NOT [medline]/lim

## CINAHL Search Strategy

ID	Searches			
S1	MH ( (MH "Cannabis+") ) OR TI ( cannabis OR marijuana OR marihuana ) OR AB (			
	cannabis OR marijuana OR marihuana)			
S2	MH ( ( MH "Tobacco") OR (MH "Smoking") OR (MH "Tobacco Products") ) OR TI (			
	cigar* OR smok* OR nicotin* OR tobacco ) OR AB ( cigar* OR smok* OR nicotir			
	OR tobacco )			
S3	MH ( (MH "Bipolar Disorder+") OR (MH "Affective Disorders+") ) OR TI ( "mood			
	disorder*" OR depress* OR bipolar OR dysthymia ) OR AB ( "mood disorder*" OR			
	depress* OR bipolar OR dysthymia )			
S4	MH (MH "Anxiety Disorders+") OR TI ( phobia* OR panic OR anxi* ) OR AB (			
	phobia* OR panic OR anxi* )			
S5	MH (MH "Psychotic Disorders+") OR TI ( psychosis OR schizo* OR psychotic) OR			
	AB ( psychosis OR schizo* OR psychotic)			
S6	MH (MH "Mental Disorders") OR TI ( "mental illness*" OR "mental disorder*" OR			
	"psychiatric disorder*" OR "psychiatric diagnos*" ) OR AB ( "mental illness*" OR			
	"mental disorder*" OR "psychiatric disorder*" OR "psychiatric diagnos*")			
S7	MH ( (MH "Case Control Studies+") OR (MH "Prospective Studies") ) OR TI (			
	"cohort stud*" OR "case control stud*" OR retrospective OR prospective OR			
	longitudinal OR inciden* OR "follow up" ) OR AB ( "cohort stud*" OR "case control			
	stud*" OR retrospective OR prospective OR longitudinal OR inciden*)			
S8	S1 OR S2			
S9	OR/S3 – S6			
S10	S7 AND S8 AND S9			

## (NB: '+' indicates that subject heading exploded in search)

## <u>PsycINFO</u>

ID	Searches
#1	Index Terms: {Cannabis} OR {Hashish} OR {Marijuana} OR {Cannabis Use
	Disorder} OR Title: cannabis OR Title: marijuana OR Title: marihuana OR Abstract:
	cannabis OR Abstract: marijuana OR Abstract: marihuana
#2	Index Terms: {Tobacco Smoking} OR {Smokeless Tobacco} OR {Tobacco Use
	Disorder} OR Title: cigar* OR Title: smok* OR Title: nicotin* OR Title: tobacco OR
	Abstract: cigar* OR Abstract: smok* OR Abstract: nicotin* OR Abstract: tobacco
#3	Index Terms: {Psychosis} OR {Schizophrenia} OR {Acute Psychosis} OR {Affective
	Psychosis OR (Serious Mental Illness) OR Title: psychosis OR Title: schizo* OR
	Title: psychotic OR Abstract: psychosis OR Abstract: schizo* OR Abstract:
	psychotic
#4	Index Terms: {Seasonal Affective Disorder} OR {Major Depression} OR {Disruptive
	Mood Dysregulation Disorder} OR (Affective Disorders) OR (Mania) OR
	{Cyclothymic Disorder} OR {Dysthymic Disorder} OR {Bipolar II Disorder} OR
	{Bipolar I Disorder} OR {Bipolar Disorder} OR Title: "mood disorder*" OR depress*
	OR bipolar OR dysthymia OR Abstract: "mood disorder*" OR depress* OR bipolar
	OR dysthymia
#5	Index Terms: {Anxiety Disorders} OR {Generalized Anxiety Disorder} OR {Panic

	Attack} OR {Panic Disorder} OR {Phobias} OR Title: phobia* OR Title: panic OR			
	Title: anxi* OR Abstract: phobia* OR Abstract: panic OR Abstract: anxi*			
#6	Index Terms: {Mental Disorders} OR Title: "mental illness*" OR "mental disorder*"			
	OR "psychiatric disorder*" OR "psychiatric diagnos*" OR Abstract: "mental illness*"			
	OR "mental disorder*" OR "psychiatric disorder*" OR "psychiatric diagnos*"			
#7	Index Terms: {Epidemiology} OR {Longitudinal Studies} OR {Prospective Studies			
	OR (Followup Studies) OR (Retrospective Studies) OR Title: "cohort stud*" OR			
	"case control stud*" OR retrospective OR prospective OR longitudinal OR inciden*			
	OR "follow up" OR Abstract: "cohort stud*" OR "case control stud*" OR			
	retrospective OR prospective OR longitudinal OR inciden*			
#8	#1 OR #2			
#9	OR/#3-6			
#10	#7 AND #8 AND #9			

### ProQuest Dissertation + Theses

S1	diskw.Exact("Cannabis") OR ti(cannabis OR marijuana OR marihuana) OR ab(cannabis	
	OR marijuana OR marihuana)	
S2	diskw.Exact("Tobacco") OR ti(cigar* OR smok* OR nicotin* OR tobacco) OR ab(cigar* OR	
	smok* OR nicotin* OR tobacco)	
S3	diskw.Exact("Psychotic") OR ti(psychosis OR schizophren* OR schizoaff* OR schizoty* OR	
	psychotic) OR ab(psychosis OR schizophren* OR schizoaff* OR schizoty* OR psychotic)	
S4	diskw.Exact("Depression" OR "Bipolar disorder") OR ti("mood disorder*" OR depress* OR	
	bipolar OR dysthymia) OR ab("mood disorder*" OR depress* OR bipolar OR dysthymia)	
S5 diskw.Exact("Anxiety disorders") OR ti(anxi* OR phobia* OR panic) OR ab(anxi*		
	phobia* OR panic OR)	
S6 diskw.Exact("Mental illness") OR ti("mental illness*" OR "mental disorder*" OF		
	disorder*" OR "psychiatric diagnos*") OR ab ("mental illness*" OR "mental disorder*" OR	
	"psychiatric disorder*" OR "psychiatric diagnos*")	
S7	diskw.Exact("Epidemiologic Studies" OR "Cohort study" OR "Case-control study") OR	
	ti("cohort studies" OR "cohort study" OR "case control studies" OR "case control study" OR	
	retrospective OR prospective OR longitudinal OR inciden* OR "follow up") OR ab("cohort	
	studies" OR "cohort study" OR "case control studies" OR "case control study" OR	
	retrospective OR prospective OR longitudinal OR inciden*)	
S8	S1 OR S2	
S9	OR/S3-S6	
S10	S7 AND S8 AND S9	

eMethods 4. PECOS inclusion/exclusion criteria

Population  Broadly representative of general population  Can be selected on basic demographics (e.g. age, sex, ethnicity, occupation), but not eligible if comprised of persons with particular health characteristics (e.g. chronic condition) or other clinically relevant factors (e.g. pregnancy, incarcerated adults, 'high-risk')  Any measure of tobacco product use (e.g. current smoking, ever smoking, cigarettes per day); excluding products not containing tobacco leaf (e.g. ecigarettes)  Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)  Any measure of cannabis-tobacco co-use (e.g. concurrent use, coadministration)  Comparator  Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = couse, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qua	Description				
occupation), but not eligible if comprised of persons with particular health characteristics (e.g. chronic condition) or other clinically relevant factors (e.g. pregnancy, incarcerated adults, 'high-risk')  • Any measure of tobacco product use (e.g. current smoking, ever smoking, cigarettes per day); excluding products not containing tobacco leaf (e.g. ecigarettes)  • Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)  • Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator  • Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  • Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  • Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  • Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  • Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  • No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  • Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  • Cungitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  • Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	Population				
characteristics (e.g. chronic condition) or other clinically relevant factors (e.g. pregnancy, incarcerated adults, 'high-risk')  Any measure of tobacco product use (e.g. current smoking, ever smoking, cigarettes per day); excluding products not containing tobacco leaf (e.g. ecigarettes)  Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)  Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator  Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Study  Design  Charles adults and in-vitro studies are excluded.					
(e.g. pregnancy, incarcerated adults, 'high-risk')					
Any measure of tobacco product use (e.g. current smoking, ever smoking, cigarettes per day); excluding products not containing tobacco leaf (e.g. ecigarettes)     Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)     Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator     Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)     Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome     Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD     Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")     Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)     No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses     Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		characteristics (e.g. chronic condition) or other clinically relevant factors			
cigarettes per day); excluding products not containing tobacco leaf (e.g. e-cigarettes)  Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)  Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator  Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		(e.g. pregnancy, incarcerated adults, 'high-risk')			
cigarettes)  Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)  Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator  Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	Exposure	Any measure of tobacco product use (e.g. current smoking, ever smoking,			
Any measure of recreational cannabis use (e.g. current use, ever use, lifetime frequency)     Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator  Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)     Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD     Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")     Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)     No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses     Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study Design  Study Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)     Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		cigarettes per day); excluding products not containing tobacco leaf (e.g. e-			
lifetime frequency     Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)		cigarettes)			
Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-administration)  Comparator     Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)     Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD     Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")      Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)     No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses      Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Study  Design  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		Any measure of recreational cannabis use (e.g. current use, ever use,			
## Comparator    Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = couse, ref = tobacco use)    Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible    Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD    Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")    Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)    No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses    Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)    Study		lifetime frequency)			
## Comparator    Eligible comparators are: (1) 'non-exposed' (e.g. never use, non-use, past year non-use, non-regular use); (2) other eligible exposures (e.g. exp = couse, ref = tobacco use)    Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible    Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD    Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")    Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)    No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses    Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)    Study		Any measure of cannabis-tobacco co-use (e.g. concurrent use, co-			
year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		, -			
year non-use, non-regular use); (2) other eligible exposures (e.g. exp = co-use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	Comparator	,			
use, ref = tobacco use)  Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	•	, , , , , , , , , , , , , , , , , , , ,			
Comparators of only lower frequency use groups (e.g. >=20CPD vs >=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
>=10CPD) or absence of problematic use (e.g. CUD vs no CUD) are not eligible  Outcome  Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD     Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")     Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)     No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses     Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study Design     Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)     Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
<ul> <li>Can be any mood, anxiety or psychotic disorder except for substance-induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD</li> <li>Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")</li> <li>Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)</li> <li>No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses</li> <li>Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)</li> <li>Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		, , , , , , , , , , , , , , , , , , , ,			
induced disorders (e.g. cannabis-induced psychotic disorder) and outcomes that only measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an incident condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	Outcome	-			
that <i>only</i> measure OCD or PTSD  Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  Must be a binary measure of an <i>incident</i> condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	Outcome				
<ul> <li>Can be composite measures (e.g. "any mood disorder") or specific conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")</li> <li>Must be a binary measure of an <i>incident</i> condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)</li> <li>No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses</li> <li>Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)</li> <li>Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		· · · · · · · · · · · · · · · · · · ·			
conditions (e.g. depressive symptoms), but not eligible if combined across disorder groups (e.g. "any mental illness")  • Must be a binary measure of an <i>incident</i> condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  • No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  • Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Study  Design  • Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  • Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
disorder groups (e.g. "any mental illness")  Must be a binary measure of an <i>incident</i> condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
<ul> <li>Must be a binary measure of an <i>incident</i> condition (i.e. analysis/study excluded participants with a current/lifetime history of condition)</li> <li>No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses</li> <li>Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)</li> <li>Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		, <del>, , , , , , , , , , , , , , , , , , </del>			
excluded participants with a current/lifetime history of condition)  No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
<ul> <li>No limit on outcome measurement type, examples may include: self-rated scales, registry codes, interviews, self-reported diagnoses</li> <li>Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)</li> <li>Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		, , , , , , , , , , , , , , , , , , , ,			
scales, registry codes, interviews, self-reported diagnoses  Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)  Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
<ul> <li>Must have raw data necessary for meta-analysis or pre-calculated effect estimate (e.g. OR, RR, HR, IRR)</li> <li>Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		1			
estimate (e.g. OR, RR, HR, IRR)  • Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)  • Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.					
Longitudinal design (cohort or nested case-control) and must collect and assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)     Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		1			
<ul> <li>assess the exposure/outcome across multiple timepoints (i.e. retrospective recall not eligible)</li> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>		, -			
recall not eligible)  • Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.	_	,			
<ul> <li>Studies without original data (e.g. systematic reviews, commentaries) are excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.</li> </ul>	Design				
excluded, and case-reports, case-series, interventional studies, qualitative studies, animal studies and in-vitro studies are excluded.		1			
studies, animal studies and in-vitro studies are excluded.		, , , , , , , , , , , , , , , , , , , ,			
• No limits on article publication status, year of publication or language.					
	Other	No limits on article publication status, year of publication or language.			


### eMethods 5. Modified Newcastle Ottawa Scale (NOS)

Quality of included studies was evaluated using an adapted version of the Newcastle Ottawa Scale (NOS) for case-control and cohort studies (Wells et al., 2013)<sup>14</sup>. The adapted scale can be found in Appendix A of the online protocol (<a href="https://osf.io/5t2pu">https://osf.io/5t2pu</a>). The original scare can be found online (<a href="https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp">https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp</a>). Assessments were performed by two independent reviewers, and any disagreements were discussed between reviewers with a third reviewer consulted if a consensus could not be reached.

The NOS evaluates the quality of individual studies across selection of participants, comparability and outcome assessments. In **eTable 8**, scores on each section have been broken down by assessment area i.e. selection (S1, S2, S3, S4), comparability (C1, C2, C3) and outcome (O1, O2, O3). The NOS assigns a maximum of 9 points using a star-based system. Whilst reviews commonly employ standard cut-offs (e.g. ≥7) to denote 'low' vs 'high' risk of bias, this approach has been criticised for not providing a nuanced assessment of possible sources of bias. For example, a study could score ≥7 with limited adjustment for confounding and substantial, or unclear, loss to follow-up.

As such, in this review we employed a weighted approach in which potential risk of bias was awarded based on satisfactory approaches to key sources of bias. To be rated as 'high quality', a study must score 2 stars on items relating to confounding (5) and 1 star on items relating to attrition (8), and only score <1 star on one other item. To be rated as 'moderate quality' a study must score ≥1 on items relating to either confounding (5) or attrition (8) and may score <1 star on more than one other item. To be rated as 'low quality' a study must score <1 star on items related to confounding (5) and attrition (8). This is similar to approaches taken in other systematic reviews which assess risk factors for incident mental health conditions (e.g. Richardson et al., 2015)<sup>12</sup>. Subgroup analyses were performed based on study quality. The 'total score' and number of points allocated per domain (i.e. selection, comparability, exposure/outcome) have also been reported.

eMethods 6. Directed Acyclic Graph (DAG)



Exposures = X; Outcomes = Y; Green arrow = focal relationship; Bolded arrows represent direction of effect for group contained within bracket. Inward and outward arrows from grey shaded areas pertain to all boxes with the shaded area.

Abbreviations: SES = socioeconomic status; SU = substance use; MI = mental illness; ACEs = adverse childhood experiences; SLEs = stressful life events; QoL = quality of life.

Confounding groups: Other substance use (Green); Psychiatric comorbidity (Pink); Socioeconomic factors (Yellow); Psychological factors (Orange); Other lifestyle factors (Blue); Demographics (Purple).

eMethods 7. Confounder matrix judgement criteria

Construct	Variables Controlled		
	Adequate	Some Concerns	Inadequate
Other substance use <sup>a</sup>	Alcohol use + tobacco/cannabis use + other illicit drug use	Some but not all of the variables (e.g., alcohol use only)	None
Psychiatric comorbidity	Composite indicator of any other mental health condition <b>or</b> adjustment for other key groups	Adjustment for one other diagnostic group (e.g., anxiety disorders)	None
Socioeconomic position <sup>b</sup>	SES index <u>or</u> social class or <u>two of</u> : education, income (e.g. personal, household), unemployment, occupation	Only education, income, employment status or occupation	None
Sociodemographic factors <sup>b</sup>	Age, sex and <u>one of:</u> race/ethnicity, marital/partner status or urbanicity	Some but not all of the variables (e.g. age + urbanicity but not sex)	Only age <u>or</u> sex
Psychological factors	Two of: stressful life events, ACEs, loneliness, personality, self-esteem, social support, risk-taking externalizing behaviours, family history of mental illness, IQ/cognitive ability, quality of life	Adjustment for only one psychological factor (e.g., ACEs)	None
Lifestyle factors	Two of: physical activity, diet, adiposity, sleep, health status	Adjustment for only one lifestyle factor (e.g. diet)	None

<sup>&</sup>lt;sup>a</sup> For middle/older adult populations, adequate adjustment was alcohol-use only given the low prevalence of cannabis use and other controlled substances (e.g. cocaine, heroin) in these groups.

<sup>&</sup>lt;sup>b</sup> For adolescent populations, variables measuring family-level factors (e.g. family structure, parental income, parental education) were considered for assessment.

### eMethods 8. Statistical approach

Included studies presented varied effect estimates. For studies providing only raw data, an unadjusted risk ratio (RR) was calculated using the number of positive and negative events in the exposed group and reference group (see **Formula 1**). The same approach was applied when studies did not present crude effect estimates, to facilitate inclusion in both adjusted and unadjusted meta-analyses. For studies which fulfilled the 'rare event' assumption (i.e. outcome prevalence <15%) the odds ratio (OR) and Hazard Ratio (HR) were considered to approximate the RR. <sup>7,8</sup> Each study was checked for reported outcome prevalence, rather than assuming rare events. Where the outcome prevalence was >15%, the OR and HR were approximately transformed using the square-root transformation. <sup>8</sup> See **Formula 2** (OR  $\rightarrow$  RR) and **Formula 3** (HR  $\rightarrow$  RR). <sup>8</sup> The Incident Rate Ratio (IRR) was approximated as an HR, and treated as described (i.e. >15% converted to approximate RR using square-root transformation).

Studies which only presented effect measures stratified by population characteristics (e.g. age, sex, ethnicity) were combined using random-effects meta-analysis and included as one estimate. For studies which presented frequency of use estimates (e.g. 1-9 CPD, 19-20 CPD, ≥20CPD), only the estimate for the highest use category was used in the main meta-analysis unless there were justified reasons to extract an alternative estimate (e.g. alternative exposure level subject to multiple imputation or buffer period to reduce risk of prodromal symptoms). Adjusted and unadjusted effect estimates were extracted and pooled separately. Studies which provided estimates that were adjusted only for age and/or sex (i.e. restriction, stratification, statistical) were not included in the primary meta-analysis as they were deemed insufficiently adjusted. These were instead included in the unadjusted meta-analysis as 'minimally adjusted' estimates.

Outliers were excluded as a exploratory sensitivity analysis, defined as all studies for which upper bound of the 95% confidence interval of the study is lower than the lower bound of the pooled effect confidence interval (i.e., extremely small effects) and for which the lower bound of the 95% confidence interval of the study is higher than the higher bound of the pooled effect confidence interval (i.e., extremely large effects).

Formula 1:

$$RR_i = \frac{a_i / n_{1i}}{c_i / n_{2i}}$$

Formula 2:

$$\left\{\frac{OR(u + OR - ORu)}{1 - w + ORw}\right\}^{1/2}$$

Formula 3:

$$\left\{\frac{1-(1-w)^{\phi}}{1-(1-u)^{1/\phi}}\frac{u}{w}\right\}^{1/2}$$

#### eMethods 9. References

- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in EpidemiologyA Proposal for Reporting. *JAMA*. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008
- Moreau D, Gamble B. Conducting a meta-analysis in the age of open science: Tools, tips, and practical recommendations. *Psychological Methods*. 2022;27:426-432. doi:10.1037/met0000351
- Fluharty M, Taylor AE, Grabski M, Munafò MR. The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review. *Nicotine Tob Res*. 2017;19(1):3-13. doi:10.1093/ntr/ntw140
- Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Published 2020. Accessed February 12, 2021. www.training.cochrane.org/handbook
- Petersen JM, Barrett M, Ahrens KA, et al. The confounder matrix: A tool to assess confounding bias in systematic reviews of observational studies of etiology. *Research Synthesis Methods*. 2022;13(2):242-254. doi:10.1002/jrsm.1544
- VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607
- 7. VanderWeele T. On a square-root transformation of the odds ratio for a common outcome. *Epidemiology*. 2017;28(6):e58-e60. doi:10.1097/EDE.000000000000733
- 8. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. *Biometrics*. 2020;76(3):746-752. doi:10.1111/biom.13197
- 9. Zhang J, Yu KF. What's the Relative Risk? A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes. *JAMA*. 1998;280(19):1690-1691. doi:10.1001/jama.280.19.1690
- Ahn N, Nolde M, Krause E, et al. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. *British Journal of Clinical Pharmacology*. 2023;89(2):602-616. doi:10.1111/bcp.15583
- 11. Hunter A, Murray R, Asher L, Leonardi-Bee J. The Effects of Tobacco Smoking, and Prenatal Tobacco Smoke Exposure, on Risk of Schizophrenia: A Systematic Review and Meta-Analysis. *Nicotine & Tobacco Research*. 2020;22(1):3-10. doi:10.1093/ntr/nty160
- 12. Richardson R, Westley T, Gariépy G, Austin N, Nandi A. Neighborhood socioeconomic conditions and depression: a systematic review and meta-analysis. *Soc Psychiatry Psychiatr Epidemiol*. 2015;50(11):1641-1656. doi:10.1007/s00127-015-1092-4
- 13. Haddaway, N R, Grainger, M. J., Gray, C. T. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching. Published online February 16, 2021. doi:10.5281/ZENODO.4543513
- 14. Wells G, Shea B, O'Connell D, et al. The Nwecastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Published 2013. Accessed February 12, 2021. http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp

eTable 1. Studies excluded at full-text screening

First Author/Year	DOI/URL/PMID	Exclusion reason
Barata 2018	10.1183/13993003.congress-2018.PA1256	FT not retrieved
Bourque 2016	10.1016/j.jaac.2016.09.406	FT not retrieved
Cao 2014	10.1111/jgs.13075	FT not retrieved
Cheng 2014	N/A	FT not retrieved
Delgado 1989	https://www.researchgate.net/publication/291 745248_Cannabis_consumption_Incidence_ and_psychological_effects	FT not retrieved
Duroseau 2020	10.1016/j.jadohealth.2019.11.259	FT not retrieved
Marfatia 2009	10.1002/pds.1806	FT not retrieved
Martinez-Hernaez 2015	10.1016/S0924-9338(15)30153-X	FT not retrieved
Michal 2015	N/A	FT not retrieved
Prom-Wormley 2012	10.1007/s10519-012-9566-6	FT not retrieved
Regeer 2009	10.1016/S0924-9338(09)70293-7	FT not retrieved
Stuchlik 2015	10.1161/circ.132.suppl_3.18557	FT not retrieved
Bakhshaie 2014	10.1016/j.comppsych.2014.10.012	Duplicate
Fritz 2016	https://scholar.colorado.edu/concern/undergraduate honors theses/8910jv21p	Duplicate
Hill 2017	10.1001/jamapsychiatry.2015.3229	Duplicate
Addington 2005	10.1136/ebmh.8.3.87.	Ineligible design
Bulacia 2016	28898309	Ineligible design
Beutel 2020	10.13109/zptm.2020.66.4.355	Ineligible design
Costello 2016	10.1007/s00127-015-1168-1	Ineligible design
Fergusson 2015	10.1007/s00127-015-1070-x	Ineligible design
Kirkbride 2011	10.1136/ebmh.14.3.70	Ineligible design
Kuepper 2011	10.1016/j.schres.2011.06.012	Ineligible design
Lewinsohn 1998	10.1016/s0272-7358(98)00010-5	Ineligible design
Nishida 2007	17561673	Ineligible design
Noda 2016	10.11560/jahp.28.special_issue_129	Ineligible design
SeguíDíaz 2017	10.1016/j.semerg.2016.05.005	Ineligible design
Skosnik 2007	10.1136/ebmh.10.2.61	Ineligible design
Abuladze 2020	10.1177/2050312120974167	Not longitudinal
Agrawal 2007	10.1111/j.1360-0443.2006.01630.x	Not longitudinal
Agrawal 2017	10.1016/s2215-0366(17)30280-8	Not longitudinal
Baggio 2014	10.1515/ijamh-2013-0305	Not longitudinal
Bandiera 2015	10.1093/ntr/ntu209	Not longitudinal
Barkhuizen 2020	10.1016/j.jaac.2018.06.037	Not longitudinal
Barrera 2016	28898304	Not longitudinal
Baskak 2012	10.1016/j.psychres.2012.01.027	Not longitudinal
Bhandari 2020	10.1007/s12126-020-09371-0	Not longitudinal
Buckner 2012	10.1016/j.drugalcdep.2011.12.023	Not longitudinal
Campbell 2020	10.1080/02791072.2020.1747665	Not longitudinal
Carceller-Maicas 2014	10.20882/adicciones.127	Not longitudinal
Catalao 2022	10.1136/bmjopen-2021-059257	Not longitudinal
Chabrol 2004	10.1016/S0013-7006(04)95424-3	Not longitudinal
Chaiton 2015	10.1016/j.addbeh.2014.11.026	Not longitudinal

	10,000,000	
Chen 2002	10.1007/s00127-002-0541-z	Not longitudinal
Chéron-Launay 2011	10.1016/j.addbeh.2011.02.013	Not longitudinal
Cheung 2010	10.3109/00952991003713784	Not longitudinal
Cougle 2010	10.1093/ntr/ntq006	Not longitudinal
Cruz-Barreda 2022	10.1016/j.ypmed.2022.107156	Not longitudinal
Cunningham 2022	10.1016/j.amepre.2021.06.024	Not longitudinal
Davis 2019	10.1016/j.drugalcdep.2019.107696	Not longitudinal
Degenhardt 2001	10.1080/09652140120080732	Not longitudinal
Degenhardt 2003	10.1016/s0376-8716(03)00064-4	Not longitudinal
DeSousa 2013	10.1016/j.schres.2013.10.037	Not longitudinal
Dominguez 2010	10.1176/appi.ajp.2010.09060883	Not longitudinal
Emerson 2018	10.1016/j.mhp.2018.09.002	Not longitudinal
Espada 2011	https://www.redalyc.org/pdf/560/5601711000 2.pdf	Not longitudinal
Ferdinand 2005	10.1111/j.1360-0443.2005.01070.x	Not longitudinal
Ferdinand 2005	10.1016/j.schres.2005.07.027	Not longitudinal
Fernandez-Pujals 2015	10.1371/journal.pone.0142197	Not longitudinal
Field 2001	11817630	Not longitudinal
Geus 2004	https://www.researchgate.net/publication/289 162839 Psychotic disorders and use of c annabis Retrospective study	Not longitudinal
Gonçalves-Pinho 2019	10.1002/mpr.1813	Not longitudinal
Goodwin 2012	10.1111/j.1521-0391.2012.00263.x	Not longitudinal
Green 2000	10.2307/2676359	Not longitudinal
Haavisto 2004	10.1016/j.jad.2004.06.008	Not longitudinal
Han 2019	10.1016/j.jad.2019.07.003	Not longitudinal
Harder 2008	10.1093/aje/kwn184	Not longitudinal
Hearld 2015	10.1016/j.jad.2014.11.041	Not longitudinal
Hong 2020	10.1007/s00127-020-01945-2	Not longitudinal
Hooker 2022	10.1016/j.jpsychores.2022.110920	Not longitudinal
Jitnarin 2015	10.1093/ntr/ntu131	Not longitudinal
Kawasaki 2015	10.1539/sangyoeisei.b14011	Not longitudinal
Keskitalo-Vuokko 2016	10.1017/thg.2016.36	Not longitudinal
Kim 2021	10.3390/ijerph18189887	Not longitudinal
Kim 2022	10.1186/s12877-021-02729-2	Not longitudinal
Kiviruusu 2022	10.1180/812877-021-02729-2	Not longitudinal
Liu 2022	10.1080/08039488.2021.2019912	Not longitudinal
Livne 2021	10.1176/appi.ajp.2021.21010073	Not longitudinal
Lyons 2008	10.1080/14622200701705332	Not longitudinal
Martínez-Ortega 2013	10.1016/j.jpsychires.2013.03.012	Not longitudinal
Martín-Merino 2010	10.4088/PCC.08m00764blu	Not longitudinal
Martín-Merino 2010	10.1093/fampra/cmp071	Not longitudinal
Massak 2008	10.1080/14622200802163449	Not longitudinal
McCaffery 2008	10.1037/0278-6133.27.3(suppl.).s207	Not longitudinal
McGrath 2010	10.1001/archgenpsychiatry.2010.6	Not longitudinal
McGrath 2016	10.1177/0004867415587341	Not longitudinal
Miettunen 2008	10.1192/bjp.bp.107.045740	Not longitudinal
Mykletun 2007	10.1016/j.eurpsy.2007.10.005	Not longitudinal

Nesvåg 2017	10.1093/schbul/sbw101	Not longitudinal
Noh 2014	10.4306/pi.2014.11.3.272	Not longitudinal
Park 2013	10.1097/jan.0b013e3182a4cad3	Not longitudinal
Pedersen 2009	10.4045/tidsskr.09.34699	Not longitudinal
Punjani 2018	10.1177/1557988318799022	Not longitudinal
Purborini 2021	10.1016/j.jfma.2021.01.016	Not longitudinal
Quadros 2020	10.1590/0034-7167-2018-0162	Not longitudinal
Rabiee 2020	10.1016/j.drugalcdep.2020.108332	Not longitudinal
Radhakrishnan 2019	10.1017/s0033291718002635	Not longitudinal
Riala 2005	http://jultika.oulu.fi/Record/isbn951-42-7495-4	Not longitudinal
Romans 1993	10.3109/00048679309075795	Not longitudinal
Rougemont-Bücking 2019	10.1080/02791072.2019.1571258	Not longitudinal
Santangelo 2018	10.4081/mi.2018.7649	Not longitudinal
Scholes-Balog 2013	10.1016/j.adolescence.2013.03.001	Not longitudinal
Shevlin 2017	10.1108/dat-03-2017-0014	Not longitudinal
Sideli 2015	10.1111/eip.12285	Not longitudinal
Slomp 2019	10.2147/NDT.S217069	Not longitudinal
Son 1997	10.1093/oxfordjournals.aje.a009081	Not longitudinal
Sourander 2004	10.1097/01.chi.0000134493.88549.e2	Not longitudinal
Stefanis 1976	10.1111/j.1749-6632.1976.tb49885.x	Not longitudinal
Van der Pol 2013	10.1111/add.12196	Not longitudinal
Yunis 2003	10.2224/sbp.2003.31.5.461	Not longitudinal
Zablocki 1991	10.2307/2136800	Not longitudinal
Zvolensky 2008	10.1016/j.jpsychires.2006.09.012	Not longitudinal
Andreas 2021	10.1177/00048674211025711	No X/Y association
Benjet 2015	10.1007/s00787-015-0721-5	No X/Y association
Bierhoff 2019	10.1080/10826084.2019.1581220	No X/Y association
Boffin 2012	10.1093/fampra/cms024	No X/Y association
Bogren 2009	https://lup.lub.lu.se/search/publication/14842	No X/Y association
Bratlien 2014	10.1016/j.psychres.2013.12.048	No X/Y association
Brook 2010	10.1093/ntr/ntq027	No X/Y association
Cartier 2017	10.4158/ep161456.Or	No X/Y association
Conde-Sala 2018	10.1016/j.jad.2018.10.358	No X/Y association
Crane 2015	10.1016/j.addbeh.2015.05.014	No X/Y association
Crespo 2022	10.1016/j.ypmed.2021.106932	No X/Y association
deGraaf 2002	10.1034/j.1600-0447.2002.01397.x	No X/Y association
deGraaf 2013	10.1016/j.jad.2013.01.009	No X/Y association
Filatova 2016	10.1017/s2045796016000123	No X/Y association
Forsell 1999	https://pubmed.ncbi.nlm.nih.gov/10389040/	No X/Y association
Grant 2008	10.1038/mp.2008.41	No X/Y association
Harris 2005	10.1093/ageing/afi216	No X/Y association
Hofstra 2002	10.1097/00004583-200202000-00012	No X/Y association
Holley 2006	10.1097/01.jgp.0000192504.48810.cb	No X/Y association
Kang 2015	10.1017/s1041610215001301	No X/Y association
Kim 2006	10.1192/bjp.bp.105.015032	No X/Y association
	10.1007/s00127-007-0171-6	No X/Y association
Köhler 2007	10.100//S0012/-00/-01/1-b	INO VIT ASSOCIATION

Mazza 2008	10.1177/0272431608324193	No X/Y association
Misawa 2018	10.1080/13607863.2018.1496225	No X/Y association
Mojtabai 2004	10.1017/s0033291703001764	No X/Y association
Moutinho 2019	10.1017/s0033291703001704 10.1016/j.psychres.2019.02.041	No X/Y association
Ogasawara 2011	10.1016/j.jad.2010.06.015	No X/Y association
Phifer 1986	10.1037/0021-843x.95.3.282	No X/Y association
Reinherz 1993		
	10.1097/00004583-199311000-00007	No X/Y association
Shedler 1990	10.1037//0003-066x.45.5.612	No X/Y association
Smit 2004	10.1016/j.jad.2003.08.007	No X/Y association
Stek 2006	10.1192/bjp.188.1.65	No X/Y association
Uemura 2017	10.1002/gps.4776	No X/Y association
vanGool 2003	10.1093/ageing/32.1.81	No X/Y association
Weinstein 2013	10.1037/a0031488	No X/Y association
Welzel 2021	10.3390/ijerph182312786	No X/Y association
Whitbeck 2009	10.1016/j.addbeh.2008.12.009	No X/Y association
Yu 2016	10.1016/j.addbeh.2016.02.007	No X/Y association
Aneshensel 1983	10.1037//0021-843x.92.2.134	Not binary
Anglin 2012	10.1016/j.schres.2012.01.019	Not binary
Anstey 2009	10.1097/PSY.0b013e3181beab60	Not binary
Arria 2016	10.1016/j.drugalcdep.2015.12.009	Not binary
Assari 2018	10.3389/fpsyg.2018.02135	Not binary
Audrain-McGovern 2009	10.1111/j.1360-0443.2009.02617.x	Not binary
Baggio 2014	10.1111/add.12490	Not binary
Bares 2014	10.1080/15504263.2014.961852	Not binary
Beal 2014	10.1007/s11121-013-0402-x	Not binary
Bilsky 2021	10.1016/j.addbeh.2021.106981	Not binary
Block 1991	10.1037//0022-3514.60.5.726	Not binary
Bourque 2018	10.1001/jamapsychiatry.2018.1330	Not binary
Brook 2006	10.2466/pr0.99.2.421-438	Not binary
Brook 2013	10.2466/15.13.PR0.113x26z6	Not binary
Caldeira 2012	10.1016/j.drugalcdep.2012.02.022	Not binary
Campbell 2020	10.1186/s40695-020-00050-3	Not binary
Capaldi 2022	10.1177/11782218221096154	Not binary
Chang 2018	10.1007/s10802-018-0414-x	Not binary
DeBoer 2021	10.1017/S0033291721002968	Not binary
Duncan 2021	10.1007/s00127-020-01900-1	Not binary
Duperrouzel 2018	10.1007/s00127-020-01900-1 10.1016/j.addbeh.2017.11.005	Not binary
Fergusson 2015	10.1016/j.addbeir.2017.11.003	Not binary
	10.1016/82215-0366(15)00208-4 10.1037/0893-164x.22.2.186	•
Fleming 2008		Not binary
Frost 1999	10.1037/h0080411	Not binary
Griffith-Lendering 2011	10.1016/j.drugalcdep.2010.11.024	Not binary
Griffith-Lendering 2013	10.1111/add.12050	Not binary
Grunberg 2015	10.1037/adb0000109	Not binary
Gunn 2020	10.1037/pha0000357	Not binary
Guttmannova 2017	10.1016/j.drugalcdep.2017.06.016	Not binary
Hoffmann 2018	10.4236/health.2018.108080	Not binary
Hooshmand 2012	10.1016/j.jadohealth.2011.05.016	Not binary

Horwood 2012	10.1016/j.drugalcdep.2012.06.002	Not binary
Hossain 2019	10.1016/j.jad.2019.06.001	Not binary
Leadbeater 2019	10.1111/add.14459	Not binary
Lee 2021	https://www.proquest.com/docview/24543570 25?pq-origsite=gscholar&fromopenview=true	Not binary
Lin 2014	10.1016/j.ridd.2014.07.018	Not binary
London-Nadeau 2021	10.1037/abn0000542	Not binary
Magee 2020	10.1016/j.addbeh.2020.106641	Not binary
Marsden 2019	10.1016/j.addbeh.2019.106078	Not binary
McIntyre 2020	https://www.proquest.com/openview/bb5b57a 9f10550e75cd5ff6f0f0172c3/1?pq- origsite=gscholar&cbl=18750&diss=y	Not binary
Meier 2020	10.1007/s10802-020-00641-8	Not binary
Melamed 2020	10.1111/sjop.12699	Not binary
Mino 2001	10.1006/pmed.2000.0803	Not binary
Moylan 2013	10.1371/journal.pone.0063252	Not binary
Munafò 2008	10.1111/j.1360-0443.2007.02052.x	Not binary
Nault-Briere 2011	https://papyrus.bib.umontreal.ca/xmlui/handle/1866/6150	Not binary
Needham 2007	10.1016/j.socscimed.2007.04.037	Not binary
Newcomb 1993	10.1037/1064-1297.1.1-4.215	Not binary
Newcomb 1999	10.1002/(SICI)1520- 6629(199907)27:4<405::AID- JCOP4>3.0.CO;2-2	Not binary
Ostrowsky 2006	https://psycnet.apa.org/record/2007-99015- 033	Not binary
Otten 2013	10.1111/j.1369-1600.2011.00380.x	Not binary
Otten 2017	10.1111/adb.12372	Not binary
Pahl 2011	10.1017/s0033291710002345	Not binary
Patten 2010	10.1177/070674371005501006	Not binary
Pedersen 2009	10.1111/j.1360-0443.2008.02395.x	Not binary
Piumatti 2018	10.1016/j.psychres.2017.12.009	Not binary
Poole 2018	10.1007/s12529-017-9703-y	Not binary
Ranjit 2019	10.1007/s11121-019-01020-6	Not binary
Ranjit 2019	10.1016/j.drugalcdep.2019.03.012	Not binary
Repetto 2005	10.1037/0278-6133.24.2.209	Not binary
Repetto 2008	10.1111/j.1532-7795.2008.00566.x	Not binary
Sarris 2020	10.1186/s12916-020-01813-5	Not binary
Schaefer 2021	10.1037/abn0000701	Not binary
Scholes-Balog 2015	10.1177/0272431614540526	Not binary
Scholes-Balog 2016	10.1016/j.addbeh.2015.09.008	Not binary
Schuler 2015	10.1016/j.drugalcdep.2015.10.005	Not binary
Shanahan 2021	10.1016/j.drugalcdep.2021.109063	Not binary
Thompson 2018	10.1037/cbs0000090	Not binary
Thompson 2021	10.3390/ijerph18073652	Not binary
Tjora 2014	10.1111/add.12522	Not binary
Tubman 1990	10.1016/s0899-3289(10)80004-5	Not binary
Tucker 2019	10.1016/j.drugalcdep.2019.06.004	Not binary
Tully 2010	10.1017/s0954579410000490	Not binary

Vaillant 1990	10.1176/ajp.147.1.31	Not binary
vanGastel 2014	10.1016/j.schres.2014.04.023	Not binary
Velten 2018	10.1186/s12889-018-5526-2	Not binary
Vermeulen 2019	10.1016/s2215-0366(18)30424-3	Not binary
Walsh 2013	10.1007/s13142-012-0189-5	Not binary
Wang 1996	10.2466/pr0.1996.79.1.127	Not binary
Washburn 2014	10.1017/s0954579414000686	Not binary
Wilhoit 2013	https://www.proquest.com/openview/5f95346 22a345e41197b365d9beb6daa/1?pq- origsite=gscholar&cbl=18750	Not binary
Wilkinson 2016	10.1016/j.jadohealth.2016.07.010	Not binary
Wilkinson 2016	10.1016/j.addbeh.2016.03.036	Not binary
Williams 2021	10.3390/ijerph181910468	Not binary
Williams 2022	10.1097/CXA.00000000000144	Not binary
Womack 2016	10.15288/jsad.2016.77.287	Not binary
Wymbs 2014	10.15288/jsad.2014.75.269	Not binary
Xu 2010	10.1080/07399332.2010.486096	Not binary
Almeida 2006	10.1097/01.Jgp.0000192486.20308.42	Not incident
Ajdacic-Gross 2009	10.1111/j.1360-0443.2009.02640.x	Not incident
Amialchuk 2022	10.1002/hec.4469	Not incident
Anderson 2022	10.1177/13591053211072685	Not incident
Andréasson 1987	10.1016/s0140-6736(87)92620-1	Not incident
Andréasson 1989	10.1111/j.1600-0447.1989.tb10296.x	Not incident
Angst 1996	10.1192/S0007125000298383	Not incident
Anstey 2007	10.1097/JGP.0b013e31802e21d8	Not incident
Arseneault 2002	10.1136/bmj.325.7374.1212	Not incident
Bagade 2022	10.1038/s41598-022-15064-2	Not incident
Bechtold 2015	10.1037/adb0000103	Not incident
Bechtold 2016	10.1176/appi.ajp.2016.15070878	Not incident
Boden 2010	10.1192/bjp.bp.109.065912	Not incident
Boden 2020	10.1111/add.14814	Not incident
Bolanis 2020	10.1016/j.jad.2020.05.136	Not incident
Breslau 1999	10.1001/archpsyc.56.12.1141	Not incident
Brook 2002	10.1001/archpsyc.59.11.1039	Not incident
Brook 2004	10.2466/pr0.95.1.159-166	Not incident
Brook 2014	10.2105/AJPH.2014.301880	Not incident
Brook 2016	10.1016/j.addbeh.2016.06.003	Not incident
Bruin 2018	10.1002/gps.4889	Not incident
Cardno 2021	10.1176/appi.prcp.20200010	Not incident
Caspi 2005	10.1016/j.biopsych.2005.01.026	Not incident
Chan 2021	10.1111/dar.13239	Not incident
Chang 2022	10.1007/s11469-022-00912-z	Not incident
Cho 2018	10.1093/ntr/ntx270	Not incident
Copeland 2021	10.1016/j.jaac.2021.07.824	Not incident
Costello 1999	10.1207/S15374424jccp280302	Not incident
Degenhardt 2010	10.1192/bjp.bp.108.056952	Not incident
Degenhardt 2013	10.1111/j.1360-0443.2012.04015.x	Not incident
Du 2022	10.3389/fpubh.2022.913636	Not incident

Dugan 2015	10.1249/MSS.0000000000000407	Not incident
Duncan 2005	10.1093/aje/kwi219	Not incident
Feng 2018	10.1016/S0140-6736(18)32688-6	Not incident
Fergusson 1996	10.1007/bf01441571	Not incident
Fergusson 1997	10.1111/j.1360-0443.1997.tb03198.x	Not incident
Fergusson 2002	10.1046/j.1360-0443.2002.00103.x	Not incident
Fergusson 2003	10.1017/s0033291703008596	Not incident
Fergusson 2003	10.1017/s0033291702006402	Not incident
Fergusson 2005	10.1111/j.1360-0443.2005.01001.x	Not incident
Fergusson 2011	10.1007/s00127-010-0268-1	Not incident
Franco 2019	10.1016/j.drugalcdep.2019.03.003	Not incident
Frederick 1988	10.1016/0091-7435(88)90061-8	Not incident
Georgiades 2007	10.1111/j.1469-7610.2007.01740.x	Not incident
Green 2012	10.1016/j.addbeh.2012.06.008	Not incident
Green 2017	10.1080/00952990.2016.1258706	Not incident
Gueltzow 2021	10.4054/mpidr-wp-2021-017	Not incident
Guo 2021	10.1186/s12911-021-01674-9	Not incident
Hamdi 2016	https://conservancy.umn.edu/handle/11299/2	Not incident
	01036	
Hamer 2008	10.1001/archinte.168.22.2474	Not incident
Handley 2019	10.1007/s00127-018-1591-1	Not incident
Harder 2006	10.1111/j.1360-0443.2006.01545.x	Not incident
Hashmi 2022	10.1371/journal.pone.0267191	Not incident
Hayatbakhsh 2007	10.1097/chi.0b013e31802dc54d	Not incident
Hengartner 2020	10.1016/j.jad.2020.03.126	Not incident
Henquet 2005	10.1136/bmj.38267.664086.63	Not incident
Hozawa 2006	10.1016/j.ypmed.2005.12.008	Not incident
Jackson 2004	https://digitalcommons.library.tmc.edu/dissertations/AAI3155309/	Not incident
John 2004	10.1016/j.drugalcdep.2004.06.004	Not incident
Johnson 2000	10.1001/jama.284.18.2348	Not incident
Johnson 2004	10.1080/14622200412331324901	Not incident
Johnson 2006	10.1080/14622200600576644	Not incident
Jones 2018	10.1001/jamapsychiatry.2017.4271	Not incident
Kendler 1993	10.1001/archpsyc.1993.01820130038007	Not incident
Keyes 2011	10.1016/j.socscimed.2010.12.005	Not incident
Klungsøyr 2006	10.1093/aje/kwj058	Not incident
Konings 2012	10.1017/S0033291711000973	Not incident
Korhonen 2007	10.1017/s0033291706009639	Not incident
Korhonen 2011	10.1093/ntr/ntq251	Not incident
Korn 2018	10.1016/j.drugpo.2018.05.003	Not incident
Kounali 2014	10.1017/s0033291714000026	Not incident
Lavallee 2021	10.1016/j.abrep.2021.100347	Not incident
Lee 2017	10.1080/10550887.2017.1303958	Not incident
Lee 2019	10.1080/08897077.2019.1572047	Not incident
Lee 2019	10.1080/09687637.2019.1698518	Not incident
Leventhal 2008	10.1080/00952990802013367	Not incident
Lien 2009	10.1016/j.jadohealth.2009.04.011	Not incident

Lyness 2000	10.1176/appi.ajp.157.9.1499	Not incident
Manrique-Garcia 2012	10.1017/s0033291711002078	Not incident
Marmorstein 2011	10.1016/j.addbeh.2011.02.006	Not incident
Marwaha 2018	10.1093/schbul/sbx158	Not incident
Mather 2015	10.1097/JOM.000000000000504	Not incident
McGee 2000	10.1046/j.1360-0443.2000.9544912.x	Not incident
Nelson 2018	10.1177/2333721418766127	Not incident
Paffenbarger 1994	10.1111/j.1600-0447.1994.tb05796.x	Not incident
Pahwa 2012	22762903	Not incident
Pasco 2008	10.1192/bjp.bp.107.046706	Not incident
Patrick 2020	10.1016/j.drugalcdep.2020.108018	Not incident
Patton 2002	10.1136/bmj.325.7374.1195	Not incident
Patton 2006	10.1016/j.jadohealth.2005.11.027	Not incident
Rasic 2013	10.1016/j.drugalcdep.2012.09.009	Not incident
Rössler 2007	10.1016/j.schres.2007.01.002	Not incident
Rössler 2012	10.1111/j.1360-0443.2011.03760.x	Not incident
Ruggles 2017	10.1007/s10461-016-1492-9	Not incident
Schaefer 2021	10.1073/pnas.2013180118	Not incident
Schoeler 2018	10.1017/s0033291717003658	Not incident
Shidhaye 2010	10.1093/ije/dyq179	Not incident
Silberg 2003	10.1111/1469-7610.00153	Not incident
Silins 2014	10.1016/s2215-0366(14)70307-4	Not incident
Steuber 2006	10.1016/j.addbeh.2005.04.010	Not incident
Strong 2014	10.1007/s11524-013-9849-0	Not incident
Tait 2012	10.1017/s1041610212000087	Not incident
Talati 2016	10.1038/mp.2015.224	Not incident
vanGool 2007	10.2105/ajph.2004.053199	Not incident
Welham 2009	10.1017/s0033291708003760	Not incident
Weller 1985	10.1176/ajp.142.7.848	Not incident
Werneck 2022	10.1016/j.maturitas.2021.09.010	Not incident
Windle 2001	10.1037/0022-006X.69.2.215	Not incident
Windle 2004	10.1017/s0954579404040118	Not incident
Woo 2002	10.1159/000058356	Not incident
Woodruff 2010	10.1093/ntr/ntq007	Not incident
Woodward 2016	10.1007/s10519-016-9812-4	Not incident
Yoo 2016	10.1136/bmjopen-2015-008570	Not incident
Bildt 2002	10.1007/s00420-001-0299-8	Ineligible outcome
Bovasso 2001	10.1176/appi.ajp.158.12.2033	Ineligible outcome
Cougnard 2007	10.1017/s0033291706009731	Ineligible outcome
Federman 1997	10.1016/s0376-8716(96)01317-8	Ineligible outcome
Gage 2014	10.1017/s0033291714000531	Ineligible outcome
Goodman 2010	10.1111/j.1360-0443.2010.02981.x	Ineligible outcome
Gubata 2013	10.1016/j.jpsychores.2013.04.003	Ineligible outcome
Hamer 2010	10.1001/archgenpsychiatry.2010.76	Ineligible outcome
Henquet 2006	10.1016/j.jad.2006.05.002	Ineligible outcome
Kuepper 2011	10.1017/s0033291711000511	Ineligible outcome
Kuepper 2011	10.1136/bmj.d738	Ineligible outcome

Markota 2018	10.1016/j.jaac.2018.09.025	Ineligible outcome
Miettunen 2014	10.1017/s0033291713002328	Ineligible outcome
Patel 2006	10.1192/bjp.bp.106.022558	Ineligible outcome
Samuelsson 2013	10.1186/1471-2458-13-621	Ineligible outcome
Shang 2020	10.3390/cancers12061700	Ineligible outcome
Smith 2014	10.1097/adm.00000000000000000	Ineligible outcome
Suwazono 2003	10.1093/occmed/kqg102	Ineligible outcome
Tien 1990	10.1097/00005053-199017880-00001	Ineligible outcome
Tijssen 2010	10.1111/j.1600-0447.2010.01539.x	Ineligible outcome
vanOs 2021	10.1093/schbul/sbab019	Ineligible outcome
Wang 2022	10.1016/j.jpsychires.2022.10.040	Ineligible outcome
Wang 2022	10.1016/j.jad.2022.04.064	Ineligible outcome
Wiles 2006	10.1192/bjp.bp.105.012179	Ineligible outcome
Wu 1999	10.2105/ajph.89.12.1837	Ineligible outcome
Zammit 2011	10.1192/bjp.bp.111.091421	Ineligible outcome
Brown 1996	10.1097/00005768-199602000-00012	Ineligible exposure
Frisher 2005	10.1136/jech.2004.030833	Ineligible exposure
Fukunaga 2019	10.2188/jea.JE20190018	Ineligible exposure
Bach 2021	10.1016/j.psychres.2021.114109	Ineligible comparator
Breslau 1993	10.1001/archpsyc.1993.01820130033006	Ineligible comparator
Chou 2011	10.4088/JCP.09m05618gry	Ineligible comparator
Giordano 2015	10.1017/s0033291714001524	Ineligible comparator
Griesler 2008	10.1097/CHI.0b013e318185d2ad	Ineligible comparator
Griesler 2011	10.1111/j.1360-0443.2011.03403.x	Ineligible comparator
Keerthy 2021	10.1017/S003329172100386X	Ineligible comparator
Kinnunen 2006	10.2190/g652-t403-73h7-2x28	Ineligible comparator
Nay 2013	10.1016/j.psychres.2013.03.006	Ineligible comparator
Nielsen 2017	10.1017/s0033291717000162	Ineligible comparator
Pacek 2013	10.1016/j.jad.2012.11.059	Ineligible comparator
Sullivan 2018	10.1001/jamanetworkopen.2018.5174	Ineligible comparator
Martín-Santos 2010	10.1111/j.1369-1600.2009.00180.x	No OR/HR/RR/IRR
Wade 2005	10.3138/cjccj.47.4.619	No OR/HR/RR/IRR
Kirli 2016	10.1016/j.eurpsy.2016.01.526	Population
Larson 2009	10.7205/milmed-d-02-0308	Population
Galambos 2004	10.1080/01650250344000235	Missing data
Green 1992	10.1111/j.1600-0447.1992.tb03254.x	Missing data
Kivelä 1996	10.1002/(SICI)1099- 1166(199610)11:10<871::AID- GPS396>3.0.CO;2-6	Missing data
Lewinsohn 1994	10.1037/0021-843X.103.2.302	Missing data
Pedersen 2008	10.1111/j.1600-0447.2008.01259.x	Missing data
Takeuchi 2004	10.1539/joh.46.489	Missing data
Blanco 2016	10.1001/jamapsychiatry.2015.3229	Cohort overlap
Chang 2016	10.1016/j.jagp.2016.07.008	Cohort overlap
Cheng 2016	10.1016/j.jad.2016.02.023	Cohort overlap
Chigogora 2018	https://discovery.ucl.ac.uk/id/eprint/10046397	Cohort overlap
Denissoff 2022	10.1016/j.schres.2022.06.014	Cohort overlap

Denissoff 2022	10.1111/add.15881	Cohort overlap
Ernst 2021	10.1038/s41598-021-81927-9	Cohort overlap
Fann 2022	10.3390/ijerph19127300	Cohort overlap
Khaled 2012	10.1016/j.jpsychires.2011.11.011	Cohort overlap
McDowell 2018	10.1093/ije/dyy141	Cohort overlap
McLachlan 2006	https://central.bac- lac.gc.ca/.item?id=MR19113&op=pdf&app=Li brary&oclc number=298133976	Cohort overlap
Meng 2014	10.1016/j.jad.2014.02.007	Cohort overlap
Mo 2007	https://rc.library.uta.edu/uta- ir/handle/10106/682	Cohort overlap
Mojtabai 2013	10.2105/ajph.2012.300911	Cohort overlap
Moon 2010	10.1007/s10560-010-0212-y	Cohort overlap
Munafò 2016	10.1016/j.drugalcdep.2016.04.035	Cohort overlap
Patel 2018	10.1097/psy.000000000000583	Cohort overlap
Sánchez-Villegas 2008	10.1157/13117850	Cohort overlap
Tellez 2019	https://academicworks.cuny.edu/jj_etds/122/	Cohort overlap
Wen 2019	10.1136/bmjopen-2019-029529	Cohort overlap
Zammit 2010	10.1192/bjp.bp.109.070904	Cohort overlap

eTable 2. Tobacco and mood disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
Albers 2002 USA	Massachuset ts Tobacco Survey of Youth	503	4 years	General	13.49 years Adolescents	Ever smoking vs. never smoking	Depression	Kandel & Davies six-item scale ≥29	Age, sex, race, parental education, presence of household smoker, baseline depression level and rebelliousness
Almeida 2013 Australia	Health in Men Study (HIMS)	4636	~5.7 years	General	71.5 years (SD 4.1) Middle/Older	Current smoking vs non-smoking	Depression	GDS-15 ≥7	Crude
<b>An 2015</b> USA	Health and Retirement Study (HRS)	24759	≤20 years	General	60.5 years (95% CI 60.3 - 60.6) Middle/Older	Current smoking vs. non-smoking	Depression	CES-D-8 ≥3	Gender, ethnicity, education level, birth cohort, history of any psychiatric problem, alcohol consumption, age in years, marital status, household net wealth, diagnosis of chronic condition, residential region, BMI
Armstrong 2017 USA	Johns Hopkins Precursors Study (JHPS)	821	≤63 years	Medical students	26.3 years (SD 2.3) Young adult	Ever smoking vs. never smoking	Depression	Self-reported depression, antidepressant use or lifetime history of mental health treatment	Sex, race, baseline age, enrollment wave, lack of physical activity, heavy alcohol use
Bakhshaie 2015 USA	Midlife Development in the United States Survey	1406	10 years	General	43.8 years (SD 13.5) Middle/Older	Persistent smoking (daily smoking at baseline and follow-up) vs.	Depression	CIDI-SF (DSM-IV)	Age, gender and alcohol/drug use problems

	(MIDUS)					never smoking			
Bolstad 2022 Finland	Northern Finland Birth Cohort Study (NFBC86)	5279	≤17years	General	15-16 years Adolescents	Daily smoking vs. no daily smoking	Depression	Major Depression measured by ICD-10 codes recorded in national health care registers	Age, sex, lifetime parental psychiatric disorder, family structure, illicit susbtance use, alcohol use, externalizing and internalizing symptoms
<b>Beutel 2019</b> Germany	Gutenberg Health Study (GHS)	9943	5 years	General	54.3 years (SD 10.9) Middle/Older	Current smoking vs. non-smoking	Depression	PHQ-9 ≥10	Crude estimate extracted
Borges 2018 Mexico	Mexican Adolescent Mental Health Survey (MAMHS)	928	8 years	General	12-17 years Adolescent	Ever smoking vs. never smoking	Any mood disorder	WMH-CIDI	Age/cohort, sex, alcohol use, any other drug use, anxiety disorders, disruptive behaviour
Bots 2008 Finland, Italy, Netherlands	The Finland, Italy and Netherlands Elderly (FINE) Study	526	5 years	General	75.2 years Middle/Older	Current smoking vs. non-smoking	Depression	ZSDS-20 ≥48/80	Age
Breslau 1998 USA	Detroit Epidemiologi c Study	843	5 years	General	26 years Young adult	Ever daily smoking (≥1 CPD for 1+ month) vs. never daily smoking	Depression	NIMH-DIS (DSM- III-R)	Sex, early conduct problems, history of alcohol dependence
<b>Brown 1996</b> USA	Oregon Adolescent Depression Project	1471	~2 years	General	16.6 years (SD 1.2) Adolescent	Regular smoking (≥3 times per week) vs. non-regular smoking (≤2 times per week)	Depression	K-SADS and LIFE	Age, gender, race, number of biological parents in household, parental education, other psychiatric disorders (i.e. anxiety, disruptive

Cabello	Study on	5970	3-8 years	General	≥50 years	Daily smoking vs.	Depression	CIDI	behaviour disorders, alcohol dependence and other drug dependence) Age, sex, country,
2017 Ghana, India, Mexico, Russia	Global AGEing and Adult Health (SAGE)			General	Middle/Older	non-smoking	Depression		education level, employment, household income, presence of physical health condition, BMI, general health status, country, alcohol consumption, physical inactivity
Chang 2016 USA	Nurses Health Study (NHS)	21728	≤10 years	Nurses	71.4 years (SD 4.1) Middle/Older	Current smoking (≥ 25 CPD) vs. never smoking	Depression	Self-reported clinician diagnosis, SSRI use or depressive symptoms CES-D-10 ≥10 or GDS-15 ≥6	Age, sex, education level, ethnicity, social network, social class, regular caregiving to children/grandchildre n, regular caregiving to disabled/ill relatives, BMI, Mediterranean diet score, activity level, daily alcohol consumption, medical comorbidity, daily hours of sleep, sleeping difficulties, bodily pain, physical/functional limitation
Chin 2016 China	Chinese Primary Care Patients	2540	≤1 year	General	49.3 years (SD 7.0) Adult	Smoker vs. non- smoker	Depression	PHQ-9 ≥10	Sex, age, marital status, income, education level, employment status, alcohol consumtpion (y/n), exercise, comorbidities, family

Chireh 2019 Canada	National Population Health Survey (NPHS)	2,743	10 years	General	>45 years Middle/Older	Daily smoking vs. no daily smoking	Depression	CIDI-SF (DSM-III-R)	history of mental illness, visits to medical practitioners, area of residence, physician factors (e.g. sex, training) Sex, age, household income, ethnicity, high blood pressure, physical activity, BMI, family stress, traumatic events, chronic disease, heart disease
Choi 1997 USA	National Teenage Attitudes and Practices Survey (TAPS)	6863	~4 years	General	12 - 18 years Adolescent	Past-month smoking vs. never smoking	Depression	Kandel & Davies six-item scale ≥29	Age, sex, household income, perceived school performance, availability of social support, rebelliousness, participation in organised sports, ethnicity, parental educational level
Clark 2007 UK	Research with East London Adolescents: Community Health Survey (RELACHS)	1170	2 years	School students	11 - 14 years Adolescent	Ever smoking vs. never smoking	Depression	sMFQ ≥8	Age, gender, eligibility for free school meals, ethnicity, alcohol and drug-health risk behaviours, general health status, long- standing illness, overweight
Cougle 2015 USA	National Epidemiologi c Study of Alcohol and Related	27769	~3 years	General	≥18 years Adults	Past-year weekly smoking vs. past- year no weekly smoking	Any mood disorder	AUDADIS-IV (DSM-IV)	Age, income, marital status, gender, ethnicity, education, psychiatric comorbidity (i.e.

	Conditions (NESARC)								anxiety, disorder, depressive disorder, personality disorder, bipolar disorder), alcohol use and cannabis/nicotine use
Cuijpers 2007 Netherlands	Netherlands Mental Health Survey and Incidence Study (NEMESIS)	2726	2 years	General	18 - 64 years Adults	Past year smoking vs. no past year smoking	Any mood disorder	CIDI (DSM-III-R)	Age, gender, education level, employment status, neuroticism, locus of control, presence of somatic illness, parental history of psychopathology, childhood trauma (i.e. emotional neglect, psychological abuse, physical abuse, sexual abuse), lifetime psychiatric condition
Flensborg- Madsen 2011 Denmark	Copenhagen City Heart Study (CCHS-I-III))	17814	≤26 years	General	>20 years Adults	Current smoking (max. >20g per/day) vs. never smoking	Depression	ICD code for depression diagnosis recorded in national registers	Age, sex, alcohol use, education, income, number of children living at home, marital status, physical activity level
Fonseca 2021 Brazil	Longitudinal Study on the Lifestyle and Health of Unviersity Students (ELESEU)	1034	≤3 years	University students	16 - 25 years Adolescent	Past-month smoking vs. no past-month smoking	Depression	PHQ-9 ≥9	Sex
Ford 1998 USA	John Hopkins Precursors Study	1190	≤37 years	Medical students	26 years Young adult	Smoking vs. non- smoking	Depression	Self-reported diagnosis, treatment or antidepressant	Sex

	(JHPS)							medication	
Gage 2015 UK	The Avon Longitudinal Study of Parents and Children (ALSPAC)	4561	~2 years	General	~16 years Adolescent	Frequency of use (max. daily) vs. never smoking	Depression	CIS-R	Family history of depression, gender, urban dwelling, maternal education, childhood borderline personality, childhood IQ, childhood psychotic experiences, conduct disorder group membership, peer problems, victimisation, cannabis use, alcohol, other illicit drugs, depression at age 12 (anxiety model only)
Gentile 2021 Sweden	Swedish National Military Conscription Register	24041	≤48 years	Military conscripts	18.1 years (SD 0.5) Young adult	Current smoking (max.>20 CPD) vs. non-smoking	Depression	ICD code for diagnosis or antidepressant treatment	Age, sex, BMI, handgrip strength, verbal comprehension, alcohol consumption, other substance use
Goodman 2000 USA	National Longitudinal Study of Adolescent to Adult Health (Add Health)	8704	1 year	School students	15.48 (SD 1.59) Adolescent	Past month smoking vs never smoking	Depression	CES-D-20 ≥22/24; modified 18-item version of CES-D-20	Age, gender, race, parental education level, baseline depression score, smoking level at follow-up, teenager poor self-rated health, GPA, other drug use, alcohol use, delinquency, lower self-esteem, temperament, parental problematic alcohol use, parental

									understanding of teenager and perception of teenagers life, parental relationship with teenager and satisfaction with relationship
Goodwin 2013 USA	Ohio Army National Guard Health Initiative (OHARNG MHI)	1391	1 year	National Guard Soldiers	64.9% were under 35 years Adult	Persistent smoking vs. never smoking	Depression	PHQ-9 ≥2	Age,gender
Groffen 2013 USA	Health, Aging and Body Composition Study (Health ABC)	2694	≤9 years	General	73.6 years (SD 2.87) Middle/Older	Current smoking vs. never smoking	Depression	Self-reported use of antidepressant medication and/or CESD-10 ≥11	Age, sex, ethnicity, recruitment site, marital status and prevalent health conditions (e.g. CVD, diabetes, cancer)
Hahad 2022 Germany	Gutenberg Health Study (GHS)	9937	~5 years	General	54.9 years (SD 11.1) Middle/Older	Pack-years of smoking (max. ≥30 years) vs. non-smoking	Depression	PHQ-9 ≥10	Age, sex, SES, employment, shift work, retirement, relationship status, alcohol use, passive smoking, cardiovascular risk factors (e.g. BMI) and diseases, C-reactive protein
Hiles 2015 Australia	Hunter Community Study (HCS)	1145	≤5.5 years	General	65.6 years (SD 7.1) Middle/Older	Current smoking vs. non-smoking	Depression	CES-D-20 ≥16	Sex, age, inflammatory marker (IL-6), waist-to-hip ratio, steps per day, % energy from saturated fat, alcohol use, number of physical illnesses,

									quality of life
Hoveling 2022 Netherlands	Lifelines Cohort Study (LCS)	76045	~3.8 years	General	44.5 years (SD 12.0) Adults	Current smoking vs. never smoking	Depression	MINI	Age, sex, socioeconomic position (index of years of education, household income, occupational prestige)
Jackson 2019 UK	English Longitudinal Study of Aging (ELSA)	2019	≤12 years	General	65.9 years (SD 9.34) Middle/Older	Current smoking vs. never smoking	Depression	CES-D-8 ≥4	Age, sex, ethnicity, household wealth, alcohol intake, BMI and physical activity
Kang 2010 Korea	Korea Welfare Panel Study (KoWePs)	10125	6 months	Low- income	>20 years; 48.2% 20 – 44 years Adult	Past year smoking (max. ≥ two packs/day) vs. past-year non- smoking	Depression	CES-D-11 ≥16	Alcohol consumption, stressful life events, self-esteem, educational level, religion, marital status, urbanicity, household income, employment status, age, gender, depressive symptoms at baseline, health status
Khaled 2012 Canada	National Population Health Survey (NPHS)	3824	12 years	General	NR Adult	Current smoker (max. 'heavy'/>20CPD) vs. never smoker	Depression	CIDI-SF (DSM-III-R)	Crude
Kim 2022 Korea	National Health Insurance Service - Health Screening Cohort	88931	~7.7 years	General	>40 years; 38.3% 40 – 49 years Middle/Older	Current smoking (max. ≥20 CPD) vs. never smoking	Depression	ICD code for diagnosis and record of at least one prescription for antidepressants	Crude

	(NHIS- HEALS)								
Korhonen 2017 Finland	Finnish Twin Cohort	8963	≤10 years	Twins	43.7 years (SD 7.70) Middle/Older	Lifetime smoking (max. ≥20 CPD) vs. lifetime non- smoking	Depression	ICD code for at least 4 consecutive prescriptions of anti-depressants	Age, sex, social class, binge drinking, presence of somatic disease
Lam 2005 China	Hong Kong Secondary Schools	1409	1 year	General	12.7 years (SD 0.85) Adolescent	Ever smoked vs. never smoked	Depression	13-item custom scale 75th percentile	Age, sex
Leung 2012 Australia	Australian Longitudinal Study on Women's Health (ALSWH)	5740	≤13 years	General	18-23 years Young adult	Current smoking (max. >20 CPD) vs lifetime non- smoking	Depression	CES-D-10 ≥10	Sex, marital status, education level, employment status
Luijendijk 2008 Netherlands	The Rotterdam Study	2801	~5 years	General	71.0 years (SD 6.3) Middle/Older	Current smoking vs. never smoking	Any mood disorder	CES-D-20 <sup>3</sup> 16 and diagnosis via PSE	Age, sex, education, income, disability in daily living, cognitive function, BMI, blood pressure, diabetes, cholesterol, cardiovascular disease, medication
Meng 2017	National Population Health Survey (NPHS)	12227	16 years	General	>12 years Adults	Regular smoking vs. no regular smoking	Depression	CIDI-SF	Crude estimate extracted
Monroe 2021 Ireland	The Irish Longitudinal Study on Ageing (TILDA)	5309	≤6 years	General	64.4 years (SD 9.1) Middle/Older	Current smoking vs. never regular smoking	Depression	CIDI-SF	Age, sex, education level, marital status, physical activity, number of chronic conditions, number of cardiovascular conditions, number of physical limitations

Monshouwe r 2021 Netherlands	NEMESIS-II	4204	~3 years	General	18 - 64 years Adult	Frequency of use (max. >20 per day) vs no past- month use	Any mood disorder	CIDI (DSM-IV)	Age, gender, employment status, living with partner, education level, psychiatric comorbidity (i.e. anxiety disorder, SUD), physical activity, any somatic disorder, negative life events, childhood abuse
Murphy 2003 Canada	Stirling County Study (1970 – 1992)	396	22 years	General	>18 years Adult	Current smoking vs. non-smoking	Depression	DPAX-1 and DPAX-2; approximates DSM-III and DSMI-IV criteria via computerised algorithm	Crude
Najafipour 2021 Iran	Kerman Coronary Artery Disease Risk Factors Study (KERCADRS	2813	5 years	General	46.2 years (SD 15.7) Adult	Current smoking vs. non-smoking	Depression	BDI ≥31	Crude
do Nascimento 2015 Brazil	Bambuí Cohort Study of Ageing (BCSA)	701	≤11 years	General	67.4 years (SD 6.1) Middle/Older	Current smoking vs. never smoking	Depression	GHQ-12 ≥5	Crude
Park 2009 Korea	Korea Youth Panel Survey (KYPS)	1742	1 year	School students	14 - 15 years Adolescent	Continued smoking vs. never smoking	Depression	Six depressive symptoms listed in DSM-IV; cut- off: "greater than normal"	Age, gender, intact family, household income, parental education level, relationship with siblings, relationship

									with parents, parenting style, parental expectation towards education level, relationship with teachers, loneliness at school, number of friends, friends delinquency, self-esteem, number of stressors, life satisfaction, parental loss, difficulty inhibiting negative affect
Raffetti 2019 Sweden	The Kupol Cohort	2900	1 year	School students	13-14 years Adolescent	Current tobacco use vs. no tobacco use	Depression	CES-DC ≥30	Age, sex, alcohol consumption, parental education level, parent born abroad, depressive symptoms score at baseline
Ren 2021 China	China Health and Retirement Longitudinal Study (CHARLS)	10508	~3 years	General	57.62 years (SD 9.44) Middle/Older	Current smoking vs. never smoking	Depression	CES-D-10 ≥10	Age, educational level, BMI, urban/rural, marital status, alcohol consumption, digestive disease, cardiovascular disease, chronic kidney disease
Rudaz 2017 Switzerland	CoLaus/Psy CoLaus	1524	~5.5 years	General	51.4 years (SD 8.7) Middle/Older	Daily smoking vs. no daily smoking	Depression	DIGS (DSM-IV)	Age, sex, SES, family history of depression, lifetime history of subthreshold depressive disorders (i.e. dysthymia, OSDD), alcohol use disorders, drug use

									disorders, anxiety disorders, BMI, dyslipidaemia, hypertension, diabetes, inflammatory markers (i.e. IL6, TNF-a, IL- 1B, hs-CRP), childhood stressful events, adult life- event impact score, physical inactivity, neuroticism, problem- solving coping, help- seeking behaviours
Sánchez- Villegas 2021 Spain	Seguimiento University of Navarra (SUN) Cohort	15096	~11 years	University graduates	17.6% of sample were ≥50 years Adults	Number of pack- years (max. ≥20) vs. never smoked	Depression	Self-reported physician- provided diagnosis of depression	Age, sex, education level, living alone, unemployment, BMI, physical activity, total energy intake, alcohol consumption, adherence to Mediterranean diet, personality traits
Storeng 2020 Norway	Nord- Trøndelag Health Studies (HUNT2 + HUNT3)	4239	~11 years	General	55-64 years Middle/Older	Daily smoking (≥1 CPD) vs. non- regular smoking	Depression	HADS-D≥8	Age, sex, education level, marital status, presence of chronic illness, physical activity, alcohol consumption, disturbed sleep duration, excessive sitting time, low social participation
Tanaka 2011 Japan	The Komo- Ise Study	8502	7 years	General	40 - 69 years Middle/Older	Current smoking vs. never smoking	Depression	DSM-12D ≥5	Age, sex, rural/urban, education level, occupation, social network

Tomita 2020 South Africa	South African National Income Dynamics Study (SA- NIDS)	14118	≤7 years	General	>15 years; 33.1% 35 – 64 years Adult	Current smoking vs. non-smoking	Elevated symptoms	CES-D-10 ≥10	Race, age, sex, marital status, education level, employment status, household income, rural/urban
Tsai 2013 Taiwan	Taiwan Longitudinal Study on Aging (TLSA)	2145	8 years	General	>50 years; 36.5% 53 – 64 years Middle/Older	Current smoking vs. never smoking	Depression	CES-D-10 ≥10	Age, sex, level of education, psychological stress, diabetes, heart disease, IADL status, family support, audio acuity, betel quid chewing, alcohol consumption, tea consumption, physical activity
Werneck 2022 Brazil	Routine health evaluations in hospital	4032	~3.1 years	General	41.2 years (SD 7.9) Adult	Current smoking vs. non-smoking	Depression	BDI ≥10	Age, sex, length of follow-up, number of metabolic risk factors, self-rated health status, HS-CRP, physical activity, alcohol consumption
Weyerer 2013 Germany	German Study on Ageing, Cognition, Dementia (AgeCoDe Study)	2512	3 years	General	79.6 years (SD 3.5) Middle/Older	Current smoking vs. non-smoking	Elevated symptoms	GDS ≥6	Age, sex, living alone, marital status, education level, mobility impairment, vision impairment, hearing impairment, functional impairment, number of somatic comorbidities, mild cognitive impairment, subjective memory impairment, alcohol consumption, apoE4

									status
Zhang 2018	Dresden Predictor	1157	~1.4 years	General	21.03 years (SD 1.73)	Current smoking vs. non-smoking	Depression	DIS (DSM-IV)	Sex, BMI, risk level of alcohol consumption,
Germany	Study (DPS)				Young adult				physical activity, good physical health
Zimmerman 2009	Hispanic Established Population	964	2 years	General	71.7 years (SD 5.6)	Lifetime smoking (>100 cigarettes) vs. lifetime non-	Depression	CES-D-20 ≥16	Crude
Mexico	for the Epidemiologi c Study of				Middle/Older	smoking			
	the Elderly (EPESE)								

**SD** = standard deviation; **CPD** = cigarettes per day; **GDS** = Geriatric Depression Scale; **CES-D** = Centre for Epidemiologic Studies Depression Scale; **PHQ-9** = Patient Health Questionnaire; **WMH-CIDI** = World Mental Health Survey - Composite International Diagnostic Interview; **ZSDS** = Zung Self-Rating Depression Scale; **NIMH-DIS** = National Institute of Mental Health—Diagnostic Interview Schedule; **DSM-III-R** = Diagnostic and Statistical Manual of Mental Disorders, 3<sup>rd</sup> ed., Revised; **K-SADS** = Schedule for Affective Disorders and Schizophrenia for School-Age Children; **LIFE** = Longitudinal Interval Follow-up Evaluation; **CIDI** = Composite International Diagnostic Interview; **CIDI-SF** = Composite International Diagnostic Interview – Short Form; **sMFQ** = Short Mood and Feelings Questionnaire; **ICD** = International Classification of Diseases; **CIS-R** = The Clinical Interview Schedule-Revised; **DSM-IV** = Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> ed.; **PSE** = Present State Examination; **DPAX-1/2** = Depression and Anxiety Assessment; **BDI** = Beck Depression Inventory; **GHQ** = General Health Questionnaire; **CES-DC** = Center for Epidemiologic Studies Depression Scale for Children; **DIGS** = Diagnostic Interview for Genetic Studies; **HADS-D** = Hospital Anxiety and Depression Scale – Depression; **DSM-12D** = Diagnostic and Statistical Manual of Mental Disorders 12-Item Scale; **DIS** = Diagnostic Interview for Mental Disorders—Research Version

eTable 3. Tobacco and anxiety disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
Borges 2018 Mexico	MAMHS	553	8 years	General	12 – 17 years Adolescent	Ever smoking (<15 years) vs. never smoking	Any anxiety disorder	WMH-CIDI (DSM-IV)	Crude
Cougle 2015 USA	NESARC	28326	~3 years	General	≥18 years Adults	Past-year weekly smoking vs. past-year non-regular smoking	Any anxiety disorder	AUDADIS- IV (DSM- IV)	Age, income, marital status, gender, ethnicity, education, psychiatric comorbidity (i.e. depressive disorder, personality disorder, bipolar disorder), alcohol use and cannabis use
Cuijpers 2007 Netherlands	NEMESIS	2726	2 years	General	18 – 64 years Adults	Past-year smoking vs past-year non-smoking	Any anxiety disorder	CIDI (DSM-III- R)	Age, gender, education level, employment status, neuroticism, locus of control, presence of somatic illness, parental history of psychopathology, childhood trauma (i.e. emotional neglect, psychological abuse, physical abuse, sexual abuse), lifetime psychiatric condition
<b>Gage 2015</b> UK	ALSPAC	4561	~2 years	General	~16 years Adolescent	Frequency of use (max. daily) vs. never smoking	Any anxiety disorder	CIS-R	Family history of depression, gender, urban dwelling, maternal education, childhoohd borderline personality, childhood IQ, childhood psychotic experiences, conduct disorder group membership, peer problems, victimisation, cannabis use, alcohol, other illicit drugs, depression at age 12 (anxiety model only)
Isensee 2003	EDSP	2548	3.5	General	14-24 years	Tobacco use	GAD	DIA-X/M-	Age, sex

Germany			years		Young adult	(max. non- dependent regular smoking) vs. never use		CIDI	
Hahad 2022 Germany	GHS	10324	~5 years	General	54.9 years (SD 11.1)	Pack years of smoking (max. ≥30 years) vs. non-smoking	Anxiety	GAD-2 ≥3	Age, sex, SES, employment, shift work, retirement, relationship status, alcohol use, passive smoking, cardiovascular risk factors (e.g. BMI) and diseases, C-reactive protein
Monshouwer 2021 Netherlands	NEMESIS- II	4182	~3 years	General	18 - 64 years Adult	Frequency of use (max. >20 per day) vs no past-month use	Any anxiety disorder	CIDI (DSM-IV)	Age, gender, employment status, living with partner, education level, psychiatric comorbidity (i.e. mood disorder, SUD), physical activity, any somatic disorder, negative life events, childhood abuse
Monroe 2021 Ireland	TILDA	5309	≤6 years	General	64.4 years (SD 9.1) Middle/Older	Current smoking vs. never regular smoking	GAD	CIDI-SF	Age, sex, education level, marital status, physical activity, number of chronic conditions, number of cardiovascular conditions, number of physical limitations
Storeng 2020 Norway	HUNT2 + HUNT3	3728	~11 years	General	55-64 years Middle/Older	Daily smoking (≥1 CPD) vs. non-regular smoking	Anxiety	HADS-A ≥8	Age, sex, education level, marital status, presence of chronic illness, physical activity, alcohol consumption, disturbed sleep duration, excessive sitting time, low social participation
Zvolensky 2008 USA	OADP	889	NR	School students	16.6 years (SD 1.2) Adolescent	Current smoking vs non-smoking	Panic Disorder	LIFE (DSM-IV)	Crude

WMH-CIDI = World Mental Health Survey - Composite International Diagnostic Interview; CIS-R = The Clinical Interview Schedule-Revised; CIDI = Composite International Diagnostic Interview; HADS-A = Hospital Anxiety and Depression Scale – Anxiety; GAD-2 = Generalized Anxiety Disorder (2-Item); LIFE = Longitudinal Interval Follow-up Evaluation; AUDADIS-IV = Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV

eTable 4. Tobacco and psychotic disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
Kendler 2015 Sweden	Swedish Conscript Registry (2002 – 2008)	233879	~7.9 years	Military conscripts	18.3 years (SD 0.6) Young adult	Frequency of use (max. >20 CPD) vs. non- smoking	Schizophrenia	ICD code for schizophrenia diagnosis/ hospitalization	Parental education, neighbourhood deprivation, any drug abuse
<b>King 2020</b> UK	The Health Improvement Network (THIN)	907586	~6 years	General	15 – 30 years Young adult	Frequency of use (max. ≥ 20 CPD) vs. non- smoking	Schizophrenia	READ code for any non- affective psychosis	Sex, social deprivation (Townsend deprivation score)
<b>Mustonen</b> <b>2018b</b> Finland	NFBC-1986	4198	≤16 years	General	15-16 years Adolescents	Frequency of use (max. ≥10 CPD) vs. non- smoking	Any psychotic disorder	ICD code for any psychotic disorder diagnosis/ hospitalization	Age, cannabis use, alcohol consumption, other substance use, parental substance use, parental psychosis, number of psychotic experiences at baseline
Okkenhaug 2018 Norway	Young- HUNT1	60	NR	School students	16 years (SD 1.54) Adolescents	Daily smoking (≥1 CPD) vs. non-daily smoking	Schizophrenia	ICD code for schizophrenia diagnosis/ hospitalization	Crude
Weiser 2004 Israel	Israel Defense Forces Medical Corps	14248	~10.2 years	Military conscripts	16-17 years Adolescents	Frequency of use (max. ≥10 CPD) vs. non- smoking	Schizophrenia	ICD code for schizophrenia diagnosis/ hospitalization	Age, sex, other psychiatric disorder at baseline, social functioning, IQ, SES
Zammit 2003 Sweden	Swedish Conscript Registry (1969/1970)	48772	≤27 years	Military conscripts	18-20 years Young adult	Frequency of use (max. >20 CPD) vs. non- smoking	Schizophrenia	ICD code for schizophrenia diagnosis/ hospitalization	Age, sex, IQ, cannabis use, poor social integartion, other psychiatric diagnoses, urbanicity, disturbed

		behaviour in childhood, family socioeconomic status, father's occupation, family psychiatric history,
		history of problematic alcohol use

eTable 5. Cannabis and mood disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
Danielsson 2016 Sweden	Mental Health, Work and Relations Study (PART)	6719	~3 years	General	41.4 years (SD 19.1) Adult	Ever use vs. never use	Depression	MDI ≥ 20	Age, sex, other illicit drug use, alcohol consumption (AUDIT), education, place of upbringing, childhood adverse circumstances (i.e. economic deprivation and serious family tension), ethnicity, depression/anxiety at baseline
<b>Gage 2015</b> UK	ALSPAC	4561	~2 years	General	~16 years Adolescent	Lifetime frequency (cumulative) vs. never use	Depression	CIS-R	Family history of depression, gender, urban dwelling, maternal education, childhoohd borderline personality, childhood IQ, childhood psychotic experiences, conduct disorder group membership, peer problems, victimisation, cannabis use, alcohol, other illicit drugs, depression at age 12 (anxiety model only)
Manrique- Garcia 2012 Sweden	Swedish Conscript Registry	45087	≤35 years	Military conscripts	18-20 years Young adult	Lifetime frequency (max. >50) vs. never use	Any mood disorder	ICD code for hospitalization	Age, sex, prior personality disorders, IQ, disturbed behaviour in childhood, social adjustment, risky use of alcohol, smoking, early

Mustonen 2021 Finland	NFBC-1986	5038	≤17 years	General	15-16 years Adolescent	Lifetime frequency (max. ≥5 times) vs. never use	Depression	ICD-10 code for depression drawn from various national registries	adulthood socioeconomic position, use of other illicit substances, urbanicity Externalizing symptoms, daily smoking, other illicit substance use, alcohol use, family structure, parental psychiatric disorder
Paton 1977 USA	New York Schools	2400	6 months	School students	<18 years Adolescent	Past-month use vs. past- month non- use	Elevated symptoms	Custom six-item scale (e.g. unhappiness, sadness) adapted from SCL ≥22	
Rognli 2019 Norway	Young in Norway	2468	9 years	General	28.5 years Young adult	Past-year use vs. never use	Depression	ATC-code for prescription of antidepressants	Age, gender, country of birth, parental education, living with biological parents in adolescence, conduct problems, alcohol intoxication episodes, daily smoking, other illicit drug use, mental distress
vanLaar 2007 Netherlands	Netherlands Mental Health Survey and Incidence Study (NEMESIS)	3881	3 years	General	39 years (SD 12.9) Adult	Frequency of use (max. almost every day/daily) vs. no lifetime use (<5 times)	Any mood disorder	CIDI (DSM-II-R)	Gender, age, education, urbanicity, employment, partner status, neurotic personality, parental psychiatric history, traumatic events in chidlhood, lifetime alcohol-use disorders or other SUDs, lifetime psychotic symptoms and lifetime anxiety disorders

eTable 6. Cannabis and anxiety disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
<b>Danielsson 2016</b> Sweden	Mental Health, Work and Relations Study (PART)	6720	3 years	General	41.4 years (SD 19.1) Adult	Ever use vs. never use	Anxiety	> 1.75 average on SCL-10 for Anxiety	Age, sex, other illicit drug use, alcohol consumption (AUDIT), education, place of upbringing, childhood adverse circumstances (i.e. economic deprivation and serious family tension), ethnicity, depression at baseline
<b>Feingold 2016</b> USA	NESARC	28505	~3 years	General	18+ years Adult	Past-year use (max. almost daily/daily) vs. past-year non- use	Any anxiety disorder	AUDADIS-IV (DSM-IV)	Sex, age, educational level, household income, marital status, urbanicity and region, alcohol use disorders and other (noncannabis) SUDs), other psychiatric disorders at baseline (e.g. MDD).
<b>Gage 2015</b> UK	ALSPAC	4561	~2 years	General	~16 years Adolescent	Lifetime frequency (cumulative) vs. never use	Any anxiety disorder	CIS-R	Family history of depression, gender, urban dwelling, maternal education, childhoohd borderline personality, childhood IQ, childhood psychotic experiences, conduct disorder group membership, peer problems, victimisation, cannabis use, alcohol, other illicit drugs, depression at age 12 (anxiety model only)
Mustonen 2021	NFBC-1986	5038	≤17	General	15-16	Lifetime	Any	ICD-10 code	Externalizing symptoms,
			years		years	frequency	anxiety	for any	daily smoking, other illicit

Finland					Adolescent	(max. ≥5 times) vs. never use	disorder	anxiety disorder drawn from various national registries	substance use, alcohol use, family structure, parental psychiatric disorder
Rognli 2019 Norway	Young in Norway	2468	9 years	General	28.5 years Young adult	Past-year use vs. never use	Any anxiety disorder	ATC-code for prescription of anxiolytics	Age, gender, country of birth, parental education, living with biological parents in adolescence, conduct problems, alcohol intoxication episodes, daily smoking, other illicit drug use, mental distress
vanLaar 2007 Netherlands	Netherlands Mental Health Survey and Incidence Study (NEMESIS)	3854	3 years	General	39 years (SD 12.9) Adult	Frequency of use (max. almost every day/daily) vs. no lifetime use (<5 times)	Any anxiety disorder	CIDI (DSM-II-R)	Gender, age, education, urbanicity, employment, partner status, neurotic personality, parental psychiatric history, traumatic events in childhood, lifetime alcohol-use disorders or other SUDs, lifetime psychotic symptoms and lifetime mood disorders
<b>Zvolensky 2008</b> USA	OADP	889	~60 months	School students	16.6 years (SD 1.2) Adolescent	Lifetime use vs. lifetime non-use	Panic Disorder	LIFE (DSM-IV)	Age, non-cannabis drug dependence, cigarette smoking

eTable 7. Cannabis and psychotic disorder study characteristics

Record; Country	Cohort	Sample size	Follow- up length	Population	Baseline age	Exposure definition	Outcome subtype	Outcome definition	Covariates
Mustonen 2018a Finland	NFBC- 1986	5872	≤14 years	General	15-16 years Adolescent	Lifetime frequency (max. ≥5 times) vs. never use	Any psychotic disorder	ICD-10 code for any psychotic disorder drawn from various national registries	Age, prodromal psychosis, other substance use, alcohol use, daily smoking, parental psychosis
Rognli 2019 Norway	Young in Norway	2468	9 years	General	28.5 years Young adult	Past-year use vs. never use	Any psychotic disorder	ATC-code for prescription of antipsychotics	Age, gender, country of birth, parental education, living with biological parents in adolescence, conduct problems, alcohol intoxication episodes, daily smoking, other illicit drug use, mental distress
vanOs 2002 Netherlands	NEMESIS	4045	3 years	General	18 – 64 years Adult	Lifetime frequency (cumulative) vs. never use	Psychosis	Composite outcome of psychosis requiring treatment, determined via BPRS ≥4, CIDI and SCID (DSM-III-R)	Age, sex, ethnicity, marital status, education level, urbanicity and level of discrimination, other illicit drug use
Zammit 2002 Sweden	Swedish Conscript Registry	40643	≤27 years	Military conscripts	18- 20 years Young adult	Lifetime frequency (max. >50 times) vs. never use	Schizophrenia	ICD code for schizophrenia diagnosis/ hospitalization recorded in Swedish National Hospital Discharge Register	Age, sex, other psychiatric diagnoses at conscription, IQ, poor social integration, disturbed behaviour, cigarette smoking and urbanicity

eTable 8. NOS quality assessment

Study	S1	S2	S3	S4	C1	C2	C3	01	02	О3	Rating	Score
Albers 2002	1	1	0	1	0	0.5	0.5	1	1	0	Moderate	6
An 2015	1	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	7.5
Armstrong 2017	0	1	0	1	1	0.5	0	0	1	0	Moderate	4.5
Bakhshaie 2015	1	1	0.5	1	1	0.5	0	1	1	0	Moderate	7
Bolstad 2022	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Borges 2018	1	1	0	1	1	0.5	0	1	1	1	Moderate	7.5
Breslau 1998	1	1	0.5	1	1	0	0	1	1	1	Moderate	7.5
Brown 1996	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Cabello 2017	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Chang 2016	0	1	1	1	1	0.5	0.5	0	1	0	Moderate	8
Chin 2016	0	1	0	1	1	0.5	0.5	1	0	0	Moderate	5
Chireh 2019	1	1	1	1	0	0.5	0.5	1	1	0	Moderate	7
Choi 1997	1	1	0.5	1	0	0.5	0.5	1	1	0	Moderate	6.5
Clark 2007	1	1	0	1	1	0.5	0.5	1	1	1	High	8
Cougle 2015	1	1	0.5	1	1	0.5	0.5	1	1	1	High	8.5
Cuijpers 2007	1	1	0.5	1	0	0.5	0.5	1	1	1	Moderate	7.5
Danielsson 2016	1	1	0	1	1	0.5	0.5	1	1	1	High	8
Feingold 2015	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Feingold 2016	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Flensborg-Madsen 2011	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Gage 2015	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Gentile 2021	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Goodman 2000	1	1	0.5	1	1	0.5	0.5	0	1	0	Moderate	6.5
Groffen 2013	1	1	0.5	1	0	0.5	0	0	1	0	Low	5
Hahad 2022	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Hiles 2015	0	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	6.5
Hoveling 2022	1	1	0.5	1	0	0.5	0.5	1	1	0	Moderate	6.5
Jackson 2019	1	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	7.5
Kang 2010	0	1	1	1	1	0.5	0.5	1	0	0	Moderate	6

Kendler 2015	1	1	1	1	1	0.5	0	1	1	1	Moderate	8.5
King 2020	1	1	1	1	0	0	0.5	1	1	1	Moderate	7.5
Korhonen 2017	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Leung 2012	0	1	1	1	0	0.5	0	1	1	0	Low	5.5
Luijendijk 2008	1	1	1	1	0	0.5	0.5	1	1	0	Moderate	6.5
Manrique-Garcia 2012	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Monroe 2021	1	1	0.5	1	0	0.5	0.5	1	1	0	Moderate	6.5
Monshouwer 2021	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Mustonen 2018a	1	1	0	1	1	0	0	1	1	0.5	Moderate	6.5
Mustonen 2018b	1	1	1	1	1	0	0.5	1	1	0.5	Moderate	7.5
Mustonen 2021	1	1	0	1	1	0	0.5	1	1	1	Moderate	7.5
Park 2009	1	1	0	1	0	0.5	0.5	0	1	0	Moderate	5
Raffetti 2019	0	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	6.5
Ren 2021	1	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	7.5
Rognli 2019	1	1	0.5	1	1	0.5	0.5	1	1	0.5	Moderate	8
Rudaz 2017	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Sánchez-Villegas 2021	0	1	1	1	1	0.5	0.5	0	1	0	Moderate	6
Storeng 2020	1	1	1	1	1	0.5	0.5	1	1	0	Moderate	8
Tanaka 2011	1	1	0.5	1	0	0.5	0.5	0	1	0	Moderate	5.5
Tomita 2020	1	1	0.5	1	0	0.5	0	1	1	0	Low	6
Tsai 2013	1	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	7.5
van Laar 2007	1	1	0	1	1	0.5	0.5	1	1	1	High	8
van Os 2002	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Weiser 2004	1	1	1	1	0	0.5	0.5	1	1	1	Moderate	8
Werneck 2022	0	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	6.5
Weyerer 2013	0	1	0.5	1	1	0.5	0.5	1	1	0	Moderate	6.5
Zammit 2002	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Zammit 2003	1	1	1	1	1	0.5	0.5	1	1	1	High	9
Zhang 2018	1	1	0.5	1	1	0	0.5	1	1	0	Moderate	7
Zvolensky 2008	1	1	0	1	1	0	0	1	1	0	Moderate	6

eTable 9. Summary of NOS ratings and mean scores by exposure/outcome

Exposure	Outcome	K	Low (%)	Moderate (%)	High (%)	Mean (SD)
Tobacco	Mood	43	7%	77%	16%	7.01 (1.00)
Tobacco	Anxiety	7	0%	29%	71%	7.93 (0.53)
Tobacco	Psychosis	5	0%	80%	20%	8.10 (0.52)
Cannabis	Mood	7	0%	29%	71%	8.21 (0.67)
Cannabis	Anxiety	7	0%	43%	57%	7.92 (0.67)
Cannabis	Psychosis	4	0%	50%	50%	8.13 (0.88)
	Overall	59	5%	68%	27%	7.35 (1.01)

eTable 10. Luis Furuya-Kanamori (LFK) index and asymmetry rating for primary meta-analyses

Exposure	Outcome	K	LFK Index Score	Asymmetry Rating <sup>a</sup>
Tobacco	Mood	43	4.12	Major
Tobacco	Anxiety	7	-1.68	Minor
Tobacco	Psychosis	5	-3.86	Major
Cannabis	Mood	7	-0.59	No asymmetry
Cannabis	Anxiety	7	1.89	Minor
Cannabis	Psychosis	4	1.73	Minor

 $<sup>^</sup>a$  LFK index scores of ±1, between ±1 and ±2, or ±2 indicate 'no asymmetry', 'minor asymmetry', and 'major asymmetry' respectively.

eTable 11. Subgroup analyses for tobacco and mood disorders


	K	RR	95%CI	l <sup>2</sup>	Q	<b>p</b> subgroup
Overall	43	1.39	1.30-1.47	61.2%		
Age Group					5.19	0.159
Adolescent	10	1.32	1.08-1.61	36.3%		
Young adult	5	1.51	1.37-1.66	0.0%		
Adult	9	1.53	1.30-1.81	73.1%		
Middle/Older	19	1.34	1.24-1.44	51.2%		
Exposure Type					1.23	0.267
Status	25	1.34	1.24-1.44	57.0%		
Heaviness	18	1.44	1.30-1.60	50.8%		
Exposure Measure					3.57	0.311
Ever use	5	1.35	1.10-1.65	0.0%		
Current or recent use (e.g. past year)	20	1.35	1.23-1.48	64.0%		
Regular use (e.g. daily)	8	1.31	1.22-1.41	1.8%		
Frequency of use (e.g. CPD)	10	1.55	1.32-1.82	54.3%		
Outcome Type					0.05	0.826
Depression	38	1.38	1.29-1.48	63.8%		
Mood disorder	5	1.36	1.21-1.54	9.6%		
Outcome Measure					1.72	0.788
Self-reported	2	1.37	1.06-1.76	0.0%		
Scale	20	1.32	1.20-1.46	44.3%		
Interview	14	1.43	1.30-1.57	41.4%		
Composite	3	1.35	1.10-1.66	45.3%		
Registry code	4	1.53	1.13-2.07	68.8%		
High Quality (NOS)					0.01	0.907
No	36	1.38	1.29-1.47	54.9%		
Yes	7	1.36	1.13-1.65	72.9%		
Confounder Matrix (>2) <sup>a</sup>					0.39	0.530
Adequate ≤ 2	37	1.40	1.31-1.50	43.3%		
Adequate > 2	6	1.32	1.11-1.58	61.6%		
Confounder Matrix (0-4) <sup>a</sup>					4.46	0.347
Adequate = 0	5	1.22	1.05-1.42	0.0%		
Adequate = 1	14	1.43	1.31-1.56	53.4%		
Adequate = 2	18	1.42	1.25-1.62	45.6%		
Adequate = 3	4	1.27	1.10-1.48	64.1%		
Adequate = 4	2	1.60	0.67-3.81	74.3%		

<sup>&</sup>lt;sup>a</sup> Subgroup analyses informed by confounder matrix were considered on adjustment for constructs *over and above* socio-demographics and psychiatric comorbidity due to the high and low, respectively, adjustment for these constructs. Adjustment for >2, represents adjustment for over half of the remaining constructs (i.e. SES, other substance use, psychological factors and lifestyle factors).

eTable 12. Meta-regression analyses for tobacco and mood disorders


Moderator	K	Coefficient	SE	Z value	P value	95% CI
Follow-up length	43	0.0000	0.0002	0.1121	0.9108	-0.0004; 0.0005
Sample size	43	0.0000	0.0000	1.2354	0.2167	-0.0000; 0.0000

eFigure 1. PRISMA flow-chart




From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/

eFigure 2. Unadjusted meta-analysis of tobacco use and mood disorders




Heterogeneity:  $I^2 = 69\%$ ,  $\tau^2 = 0.0504$ , p < 0.01

eFigure 3. Unadjusted meta-analysis of tobacco use and anxiety disorders




Heterogeneity:  $I^2 = 72\%$ ,  $\tau^2 = 0.2035$ , p < 0.01


eFigure 4. Unadjusted meta-analysis of tobacco use and psychotic disorders




eFigure 5. Unadjusted meta-analysis of cannabis use and mood disorders



eFigure 6. Unadjusted meta-analysis of cannabis use and anxiety disorders



eFigure 7. Unadjusted meta-analysis of cannabis use and psychotic disorders



**eFigure 8.** Summary matrix for tobacco use and mood disorders

			Don	nains			Overall	
Albers 2002	X	X	×			<b>(1)</b>	×	
An 2015	0	Ð	•	X	Ð	Ð		
Armstrong 2017			× ×	× ×		0	×	
Bakhshaie 2015	X	<b>(</b>	×	X	×	Ð	×	
Bolstad 2022	X	Ð	×	•	×	•	×	
Borges 2018	×	Ð	ĕ		×	•	×	
Breslau 1998	X		×		×		×	
Brown 1996	×	<b>①</b>	ĕ		ă	<b>•</b>	×	
Cabello 2017	•	•		×	<b></b>	•	×	
Chang 2016	Ð	•	<ul><li>×</li><li>×</li><li>×</li><li>×</li></ul>	ě	Ð	Ð	×	
Chin 2016	Ð		X		Ð	Ð	×	
Chireh 2019	0	× ×	×	<b>•</b>		•	×	
Choi 1997		×	X	Ð	<b>•</b>	Ð	×	
Clark 2007	<b>(</b>	Ð	×	×		•	×	
Cougle 2015	X		ě	ě	<b>•</b>	Ð	×	
Cuijpers 2007		X	<b>•</b>	•	Ð	Ð	×	
Flensborg-Madsen 2011		ě	X	×	0	<b>•</b>	×	
Gage 2015	× ×	<b></b>	×	•		•	×	
Gentile 2021	<b>•</b>	•	X		×	•	×	
Goodman 2000	X	•	×	<b>•</b>	ĕ	•	×	control quality
Groffen 2013		×	×	×	×	Ð	×	_
Hahad 2022	<b>•</b>	ě	×	×	<b></b>	Ð	×	adequate
Hiles 2015	Ð	<b>(</b>	X		×	Ð	×	inadequate
Hoveling 2022	X	×	×	×	Ð	•	×	some concerns
Jackson 2019	•	<b>D</b>		X		•	×	
Kang 2010			X	•	<b></b>	•	×	
Korhonen 2017		<b>(</b>	X	×	Ð	Ð	×	
Leung 2012	X	×	X	×	0	•	×	
Luijendijk 2008	Ð	×	X	ă	Ð	Ð	×	
Monroe 2021	•	× ×	ă	×		Ð	×	
Monshouwer 2021	•	•		<b>•</b>	<b>•</b>	0	ă	
Park 2009	×	×		Ð	Ð	Ð	×	
Raffetti 2019	× ×	ă	× ×	×		Ð	×	
Ren 2021		<b></b>	X	×	ě	Ð	×	
Rudaz 2017	<b>•</b>	Ð		Ð	<b>•</b>	Ð	ĕ	
Sánchez-Villegas 2021	Ð		×		Ð	Ð	×	
Storeng 2020	Ð	<b>•</b>	X	ě	ă	•	$ \times \times$	
Tanaka 2011	×	×	<b>X</b>	ě	Ð	Ð	×	
Tomita 2020	× ×	×	× ×	× ×	Ð	Ð	8	
Tsai 2013	•	•		•		Ð		
Werneck 2022	Ð	Ö	× ×	× ×	× ×	Ð	×	
Weyerer 2013		<b>•</b>	X	×	ĕ	<b>•</b>	× ×	
Zhang 2018	•		×	×	×		×	
-		ø,				S.	=	
	Other lifestyle factors	Other substance use	rbidi	Psychological factors	SES	Sociodemographics	Overall S	
	yle f	tanc	ошо	<u>a</u>		logra	O	
	fest	sqns	<u>0</u>	logic		qem		
	Jer II	Jer s	hiatr	/cho		ocio		
	₹	₫	Psychiatric comorbidity	Ps		Ø		

eFigure 9. Summary matrix for tobacco use and anxiety disorders

			Dom	nains			Overall	
Cougle 2015	×	•	•	•	•	•	×	
Cuijpers 2007	•	×	•	<b>①</b>	•	•	8	
Gage 2015	×	•	•	<b>•</b>	•	•	×	control quality
Hahad 2002	<b>•</b>	•	×	×	<b>•</b>	•	×	adequate inadequate
Monroe 2021	<b>•</b>	×	•	<b>①</b>	•	•	×	some concerns
Monshouwer 2021	<b>①</b>	<b>•</b>		<b>①</b>	<b>+</b>	•	•	
Storeng 2020	<b>•</b>	•	×	•	•	•	8	
	Other lifestyle factors	Other substance use	Psychiatric comorbidity	Psychological factors	SES	Sociodemographics	Overall	

**eFigure 10.** Summary matrix for tobacco use and psychotic disorders

			Domains				Overall	
Kendler 2015	×	•	×	×	<b>•</b>	•	8	
King 2020	<b>×</b>	×	×	<b>×</b>	•	•	8	control quality
Mustonen 2018	×	•	×	•	×	•	8	adequate inadequate some concerns
Weiser 2004	×	×	<b>•</b>	•	<b>•</b>	•	8	
Zammit 2003	×	•	<b>•</b>	<b>①</b>	<b>①</b>	•	<b>&amp;</b>	
	Other lifestyle factors	Other substance use	Psychiatric comorbidity	Psychological factors	SES	Sociodemographics	Overall	

**eFigure 11.** Summary matrix for cannabis use and mood disorders

			Domains				Overall	
Danielsson 2016	<b>&amp;</b>		•	•	•	•	8	
Feingold 2015	X	•	•	×	•	•	×	
Gage 2015	<b>×</b>	•	•	<b>•</b>	•	•	×	control quality
Manrique-Garcia 2012	×	•	•	•	•	•	<b>&amp;</b>	adequate     inadequate     some concerns
Mustonen 2021	×	•	<b>•</b>	<b>①</b>	×	•	×	
Rognli 2019	<b>×</b>	•	•	•	•	•	8	
vanLaar 2007	×	•	•	•	•	•	×	
	Other lifestyle factors	Other substance use	Psychiatric comorbidity	Psychological factors	SES	Sociodemographics	Overall	


**eFigure 12.** Summary matrix for cannabis use and anxiety disorders

			Dom	nains			Overall	
Danielsson 2016	×	•	•	•	•	<b>①</b>	8	
Feingold 2016	X	•	<b>•</b>	×	<b>•</b>	•	8	
Gage 2015	×	<b></b>	•	<b>①</b>	•	<b>•</b>	×	control quality
Mustonen 2021	×	<b>•</b>	<b>•</b>	•	×	•	8	adequate     inadequate     some concerns
Rognli 2019	X	<b>(</b>	<b>•</b>	•	•	•	8	Some someons
vanLaar 2007	×	+	•	<b></b>	<b></b>	<b>•</b>	×	
Zvolensky 2008	×	0	×	×	×	•	×	
	Other lifestyle factors	Other substance use	Psychiatric comorbidity	Psychological factors	SES	Sociodemographics	Overall	


**eFigure 13.** Summary matrix for cannabis use and psychotic disorders

			Domains				Overall			
Mustonen 2018a	×	<b>①</b>	X	•	X		×			
Rognli 2019	×	•	•	•	•	•	×	<b>+</b> :	trol quality adequate inadequate some concerns	
vanOs 2002	X	X	X	×	•	•	X			
Zammit 2002	X	X	•	•	X	<b>(</b>	×			
	Other lifestyle factors	Other substance use	<sup>5</sup> sychiatric comorbidity	Psychological factors	SES	Sociodemographics	Overall			


eFigure 14. Doi plot and LFK index for tobacco use and mood disorders




eFigure 15. Doi plot and LFK index for tobacco use and anxiety disorders




eFigure 16. Doi plot and LFK index for tobacco use and psychotic disorders



eFigure 17. Doi plot and LFK index for cannabis use and mood disorders



eFigure 18. Doi plot and LFK index for cannabis use and anxiety disorders



eFigure 19. Doi plot and LFK index for cannabis use and psychotic disorders

